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ABSTRACT 
Genetic variability is essential to human individuality. Genetic variation includes 
differences in sequence at the single nucleotide level to structural variations of 
large segments of DNA called copy number variations (CNVs). CNVs within a 
genome can be identified using microarray technology; however, the analysis of 
microarray results resulting in the “calling” of CNVs is not always precise. The 
research included in this manuscript describes the identification and analysis of 
CNVs using three commercially-available packages, Affymetrix
®
 Genotyping 
Console
TM
, Partek
®
 Genome Suite
TM
 and PennCNV, that are most commonly 
used in the analysis of SNP and CNV data. Specifically, this research assessed the 
ability of these platforms to successfully analyze Affymetrix
®
 Genome-Wide 
Human SNP Array 6.0 data for CNVs within two families, each with a set of 
monozygotic twins discordant for schizophrenia. Results show that the three 
methods identified a set of CNVs in each individual, but the specific sets 
identified were not identical between softwares. Affymetrix
®
 Genotyping 
Console
TM
 detected a wide variety of sizes of CNVs while the other two methods 
were able to identify only CNVs greater than 1 Mb in size.  Interestingly, all 
platforms showed that monozygotic twins differ for some CNVs, a difference that 
may be acquired during their somatic development. This suggests that CNV 
differences between monozygotic twins may offer an explanation for discordance 
of phenotype, such as schizophrenia.  Also, this analysis of CNVs within related 
individuals may identify previously unreported unusual features, including the 
repeated CNVs on chromosome 13q observed in the father of family 2. Such 
results support the use of CNV in familial studies, but argue for a careful 
assessment of CNVs including a careful selection of analysis tools and the 
necessity of independent confirmation.  
 
Key words: Copy number variants, microarray, monozygotic twin, CNV calling 
algorithms 
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Chapter 1: Introduction 
The principles of biological evolution provide the foundation for modern biology.  They 
have been instrumental in revolutionizing our understanding of the relationships between 
all life forms and can explain the extensive variability seen both between and within all 
species. This variability has evolved over time and is encoded in DNA. Some differences 
represent part of the evolutionary processes that have occurred over time and others are 
newly arisen and may or may not be passed on to the next generation. The degree, type 
and source (common or rare, polymorphic, ancient or de novo) of genetic variation that 
exists is not fully understood for most species, information  that could be used for 
understanding a species’ past and reflecting on its future in terms of survival, 
reproduction and fitness. This is particularly true for humans where an ever-increasing 
number of individual genomes are being assessed using DNA microarrays and complete 
genome sequencing. These data are organized and have been made available to 
researchers, but this rich and valuable resource remains to be analyzed and fully 
understood. Briefly, data available to date show that the human genome carries extensive 
genetic variability. One may argue that no two individuals are identical. Also, this 
variability exists in the form of a number of mutational events that include single 
nucleotide polymorphisms (SNPs), variable number of tandem repeats (VNTRs such as 
mini- and microsatellites), presence or absence of transposable elements (e.g. Alu 
elements) and structural alterations such as deletions, duplications and inversions 
including copy number variations (CNVs) that cover large (1Kb to 5Mb) DNA segments. 
Although it has been possible to identify specific events by focussing on individual genes 
and genomic regions, a full evaluation of the extent to which they may occur across an 
entire genome has become possible only recently. This opportunity has its origin in the 
complete human genome sequences generated during early 2000s (Istrail et. al., 2004). 
The availability of human genome sequence has allowed the development of novel 
technologies, including DNA microarrays that can be used to interrogate the entire 
genome (Struan et. al., 2008). The development of these technologies now allows an 
assessment of the degree and nature of DNA variability across a genome and between 
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individuals. Further, although human DNA microarray technology started with a 
relatively small number of SNP markers, modern chips now include an ever-increasing 
number of markers (>1 million) that are evenly spaced and cover the entire genome 
(Bierut et al., 2010). This allows the quantification of different types of genomic 
variations that occur on an individual basis. Of all types of genomic variations identified, 
SNPs and CNVs are probably the most commonly evaluated in most experiments 
involving humans. This is based on two facts: first, they are among the most common 
forms of genetic variation in humans, and second, they are thought to represent functional 
variations that may contribute to differences in human phenotypes such as diseases. In 
this research, I have chosen to focus on CNVs. 
1.1 Copy Number Variations (CNVs) 
CNVs represent differences in the numbers of copies of relatively large genomic regions 
(1Kb to 5 Mb) that may include a number of genes. Two fundamental studies in 2004 
pioneered the establishment of copy number variations as an important source of genetic 
differences in humans (Iafrate et al., 2004; Sebat et al., 2004).  They concluded that 
CNVs are responsible for approximately 18% of variation in gene expression and, 
subsequently, may play a vital role in the determination of complex traits (Strange et al., 
2007). The origin of CNVs at a given genomic site is not fully understood, however the 
mechanism may involve non-homologous end joining (NHEJ) or non-allelic homologous 
recombination (NAHR) (Zhang et. al., 2009). CNVs have been found to vary across 
populations in frequency distribution, with copy number polymorphisms (CNPs) 
occurring in more than 1% of a given population (Scherer et al., 2007). CNVs represent a 
novel insight into the extent of structural variation that may occur in the human genome, 
offering a new tool to understand complex traits (Li et al., 2009) and investigate the role 
of gene functions in disease (McCaroll et al., 2007). Currently, several studies have 
successfully associated human phenotypes or diseases with copy number variation. In 
fact, copy number variation (CNV) may have extensive role in genetic variability and 
human disease (Lonita-Laza et al., 2009). CNVs have been shown to functionally 
contribute to a number of autoimmune diseases (Lee et al., 2012) and cancers (Pylkas et 
al., 2012). In addition, they can determine the onset of various Mendelian diseases.   
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Interestingly, CNVs have also been shown to be associated with the variability observed 
in human complex traits, such as susceptibility to HIV infection, autism, and 
schizophrenia (Zhang et al., 2009). 
Several unique characteristics of CNVs sustain their role in human disease genetics. First, 
although less abundant than SNPs, it has been suggested that the thousands of bases 
included in a CNV locus may result in more nucleotide variation than SNPs for their size, 
given that they often encompass and may even interrupt the function of coding DNA 
sequences (Tuzun et al., 2005). Second, CNVs appear to be an enhancement of 
“environmental sensor” genes that are not essentially vital for early embryonic 
development but rather help humans to adapt to an ever-changing environment, such as 
olfactory receptors, immune and inflammatory response and ion channels genes (Sebat et 
al., 2004; Tuzun et al., 2005).  
1.2 Assessment of Genome-wide Copy Number Variations (CNVs): 
Identification and evaluation of CNVs begins with an assessment of the dosage of a given 
region of genomic DNA present in the genome. This process may use any region-specific 
dosage assessment technology if the region of the genome affected is already known or 
hypothesized. However, region-specific technologies are not practical for identification of 
CNVs across the genome, or the identification of novel CNVs. Therefore, genome-wide 
studies of CNVs typically utilize genomic arrays. This leaves us with the option of two 
technologies: comparative genomic hybridization (CGH) (Pinkel et. al., 1998), commonly 
used in the detection of gross structural changes associated with cancer tissues, or 
commercially-available SNP arrays (Huang et. al., 2004). In both cases, the identification 
of CNVs relies on the signal intensity of a stretch of DNA or a linear sequence of SNP 
markers. The SNP arrays in particular generate a large number of SNP (>1 million) signal 
intensities that are expected to be proportional to their dose. These results are then 
normalized for the amount of DNA used, experimental conditions, image analysis, plate 
and batch effects, and other experimental conditions. This is followed by a number of 
analytic methods that are expected to identify specific CNVs. However, the accuracy of 
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CNV detection is not currently ideal and results differ depending on the detection 
programs used and their parameters. 
Published literature attests that SNP arrays, particularly the Affymetrix
®
 Genome-Wide 
Human SNP Array 6.0, have become the major tool for CNV analysis in humans. These 
arrays have been designed to allow the simultaneous genotyping of a very high number of 
polymorphisms. SNP arrays typically screen from thousands to millions of SNPs for a 
given sample and have been used extensively and successfully for genome-wide 
association studies (Ragoussis, 2009). However, recent interest in the structural variation 
of the genome has led to the use of these arrays to satisfy other purposes. Intensity data 
from SNP arrays can be used to detect copy number (CN) changes and a number of 
methods have been developed to assist with this procedure. Initially, the arrays were 
optimised only for genotyping SNPs, but recent array designs now include specially-
designed probes to enable the detection of sites of known structural or copy number 
variation. These copy number polymorphisms (CNPs) can be assayed in parallel with 
other SNPs to produce a clearer picture of genome variation. At the current time, the 
Affymetrix
®
 Genome-Wide Human SNP Array 6.0 has 1.8 million probes. Since CNVs 
are events found in less than 1% of the population (Feuk et. al., 2006), this increased 
overall genomic coverage and assay density allows the detection of rare CNV changes. 
It is also apparent from the literature that different analytical methods may yield different 
sets of CNVs from the same raw (.cel file) data source. Also, attempts to confirm these 
results using independent methods including quantitative PCR are not always successful. 
Such results argue that there is a need to refine detection and analysis methods so that 
common .cel files will yield reliable and reproducible results. In this research, I have used 
a set of novel Affymetrix
®
 Genome-Wide Human SNP Array 6.0-generated .cel files 
generated from the analysis of related individuals in order to test the suitability of a set of 
commonly used analytical methods in the identification of CNVs.  The three analytical 
algorithms assessed in this research are, i) Affymetrix
®
 Genotyping Console
TM
, ii) 
Partek
®
 Genome Suite
TM
 and iii) PennCNV, all of which can use the same raw intensity 
files to filter and investigate CNVs. Three algorithms are based on a Hidden Markov 
Model (HMM) and use different copy numbers as hidden states to detect changes using 
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different approaches. The objective of this study is to evaluate these three calling 
algorithms including their biases, their stringency, and what commonalities they may 
share. 
1.3 Analytical Challenges 
There are two goals of this analysis. The first is to identify regions of the genome that 
have a higher (3+) or lower (0-1) intensity of marker probes across a given genome. Such 
results allow the identification of genomic regions where a number of continuous markers 
have either higher or lower intensity of signals as compared to the other related 
individuals or than would be expected based on known genomic data. Such regions, if 
they are between  1Kb to 5Mb in size and involve more than 20 consecutive markers, are 
flagged as regions existing in more than 3 copies (a gain) or less than 2 copies (a loss) 
within the genome and are categorized as copy number variation. The next set of analyses 
seeks to identify CNVs from Affymetrix platform (Genome-Wide Human SNP Array 6.0 
using different algorithms or packages as listed below. 
1)  Affymetrix
®
 Genotyping Console
TM
  (GTC) (http://www.affymetrix.com/). 
2)  Partek
®
 Genome Suite
TM
 (PGS) (http://www.partek.com/). 
3)  PennCNV (http://www.openbioinformatics.org/penncnv/) 
4)  dChip (http://biosun1.harvard.edu/complab/dchip/snp.htm). 
5)  QuantiSNP (http://groups.google.co.uk/group/quantisnp). 
6)  Nexus Biodiscovery (http://www.biodiscovery.com/index/nexus). 
 
Choosing an algorithm for the detection for copy number changes is dependent on the 
platform that generated the data. It is also important to take into account the factors in the 
dataset, since some algorithms provide more flexibility for adjusting parameters. Further, 
by analysing with more than one algorithm, the user can take advantage of different 
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features and strengths of individual tools, and the results can be compared to confirm 
events of interest. This study uses the first three algorithms (Affymetrix
®
 Genotyping 
Console
TM
, Partek and PennCNV) as they are most commonly used in studies examining 
human copy number variation. 
1.3.1 Affymetrix
®
 Genotyping Console
TM
  (GTC) 
GTC is a software designed for the accurate and thorough detection of single nucleotide 
polymorphisms (SNP) as well as both common and rare copy number (CNV) variants. It 
is comprised of a four-stage analytical framework for deriving integrated and mutually 
consistent copy number and SNP genotypes. These four stages are i) genotyping analysis 
using a Birdseed algorithm, ii) copy number/loss of heterozygosity analysis using a 
BRLMM-P+ algorithm, iii) common or known CNV detection using the Canary 
algorithm, and iv) rare CNV detection with the Birdseye algorithm. Birdseed is a two-
dimensional Gaussian Mixture Model (GMM). It uses normalized intensities from a set of 
.cel files that then create a N by 2*M matrix where N is the number of samples and M is 
the number of SNPs. The Canary algorithm, on the other hand, identifies regions of 
known copy-number variation. Canary is a one-dimensional Gaussian Mixture Model 
(GMM). Birdseye is specialized to discover rare or de novo regions of variable copy 
number using a Hidden Markov Model (HMM) (Korn et. al., 2008, McCarroll et. al., 
2008).  
1.3.2 Partek
®
 Genome Suite
TM
 (PGS) 
PGS is able to use Affymetrix .cel files for copy number analysis. The first step of CNV 
analysis is to estimate the number of copies of each marker (allele). This estimation is 
done by comparing each marker with reference from either paired or unpaired samples. A 
paired design assumes that each sample has its own reference sample, whereas unpaired 
samples use a common reference. PGS provides three options for selecting unpaired 
samples references: i) an existing reference file provided by Partek™ ii) a file created 
from a set of normal samples and ii) a file generated from a subset or all samples within 
the current project. The next step is the detection of regions with copy number variation. 
Starting with copy number estimates for each marker, PGS derives a list of regions where 
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adjacent markers share the same copy number using one of two offered algorithms for 
region detection: Genomic Segmentation or Hidden Markov Model (HMM). Essentially, 
both algorithms examine trends across multiple adjacent markers; the genomic 
segmentation algorithm identifies breakpoints in the data, i.e., changes in copy number 
between two neighbouring regions, while the HMM algorithm looks for discrete changes 
of copy number states (e.g., 0, 1, 2… with no upper limit) and will find regions with those 
numbers of copies. Therefore, the HMM model performs better in cases of homogenous 
samples when the copy numbers can be anticipated. Genomic segmentation is preferred 
for heterogeneous samples with unpredictable copy numbers. The number of copies of 
each marker detected in the previous step is then used to detect the genomic regions with 
copy number variation, i.e., to identify amplifications and deletions across the genome. 
Genome segmentation itself is divided into two steps. In the first step, each region is 
compared to an adjacent region in order to tell whether both have the same average copy 
number and if a breakpoint can be inserted by using a two-tailed t-test, which compares 
the average intensities of regions and if the corresponding cut-off p-value is below the p-
value threshold. The genomic size of a region is defined by the number of genomic 
markers included in the region (“minimum genomic markers”), while the magnitude of 
significant difference between two regions is controlled by the signal to noise ratio (more 
simply, this could be thought of as the difference in copy numbers between the regions). 
If the t-test is significant, it can be concluded that the region differs significantly from its 
nearest neighbours with respect to copy number. However, a second step is needed to 
identify the exact nature of the difference, i.e., whether the difference is an amplification 
or deletion. In this stage, two one-tailed t-tests are used to compare the mean copy 
number in the region with the expected (normal) diploid copy number (Diskin et. al., 
2008, Ramakrishna et. al., 2010, Yamamoto et. al., 2007). 
1.3.3 PennCNV 
PennCNV creates precise models for CNV analysis using log R Ratio and B Allele 
frequency.  This develops more realistic models for state transition between different 
copy number states to better reflect the distribution of the intensity data. In addition, 
PennCNV incorporates the population allele frequency for each SNP and the distance 
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between adjacent SNPs. The raw signal intensity values measured for the A and B alleles 
are then subject to normalization using the signal intensity of all SNPs. This procedure 
produces the two values for each SNP, representing the experiment-wide normalized 
signal intensity of the A and B alleles. Two additional measures are then calculated for 
each SNP: total signal intensity and relative allelic signal intensity ratio. As a normalized 
measure of total signal intensity, the log R Ratio (LRR) value for each SNP is then 
calculated as log2 ratio of Robserved and Rexpected, where Rexpected is computed from linear 
interpolation of canonical genotype clusters. The B Allele Frequency (BAF) is calculated 
using a normalized measure of the relative signal intensity ratio of the B and A alleles 
where AA, AB, and BB are the values for the three canonical genotype clusters generated 
from a large set of reference samples. PennCNV uses a Hidden Markov model (HMM) 
for CNV detection. HMM provides a natural statistical framework for modeling 
dependence structures between copy numbers at nearby SNPs. To detect CNVs, 
PennCNV uses the HMM that assumes that the hidden copy number state at each SNP 
depends only on the copy number state of the most preceding SNP and the values of log 
R Ratio and B allele frequency are independent (Wang et. al., 2007). 
 
1.4 Hypothesis: 
The three analytical methods of identification of CNVs from the Affymetrix 
Genome-Wide Human SNP Array 6.0 data will generate similar copy number 
variation changes in monozygotic twins. Also, the first degree relatives of these 
individuals (mother or father) will share approximately 50% of their CNVs.  
 
1.5 Specific Objectives 
a) To identify the nature of copy number variation in eight individuals 
representing two families using three CNV calling algorithms, i) GTC, ii) PGS 
and iii) PennCNV, from .cel files generated using Affymetrix
®
 Genome-Wide 
Human SNP Array 6.0. This characterization will include i) CNV size, ii) 
9 
 
chromosome distribution, iii) losses or gains and iv) de novo versus inherited 
changes.  
b)  To use CNV results (above) to establish any differences between monozygotic   
     twins discordant for schizophrenia in two unrelated families. 
 c)  To compare CNV results across platforms. 
d) To assess the suitability of the platform combination for the reliable 
identification of human CNVs.  
10 
 
Chapter 2: Materials and Methods 
2.1 Ethics Review 
Research examining genetic discordance in monozygotic twins was approved by the 
Committee on Research Involving Human Subjects at the University of Western Ontario, in 
London, Ontario, Canada (Review Number : 09390E) 
2.2 Sample Collection 
The patients and families included in this study were identified and clinically assessed by Dr. 
Richard O'Reilly, Psychiatrist, Regional Health Care, London, ON.  Informed consent was 
obtained from all participants, and relevant medical records were reviewed by Dr. O’Reilly.  
Participants were interviewed using the Structured Clinical Interview for DSM-IV (for 
personality disorders). Whole blood samples from each participant were collected by Dr. 
O’Reilly and immediately stored at -80°C. All blood samples were collected prior to the 
initiation of my research. 
2.2.1 Sample background  
Two families were assessed in this study. Each family consists of four participants, one twin 
pair and both parents, for a total of eight participants (Figure 1). Demographic information 
and relevant clinical history are listed in Table 1. 
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Figure 1: Pedigree of two families with monozygotic twins discordant for schizophrenia. 
Members of the family one are indicated with (I-) and members of the family two are 
indicated with (II-). The designations included in this figure are followed in subsequent 
figures and tables. 
Family - 2 
II-2-1 
Schizophrenia 
 
II-2-2 
II-1-1 II-1-2 
Family - 1 
I-2-1 
Schizophrenia 
 
I-2-2 
 
I-1-1 I-1-2 
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Table 1.  Demography and Clinical History of monozygotic (MZ) twins discordant for Schizophrenia (SCZ). 
 
Family one is indicated with (I-), family two is indicated with (II-). N/A = Not Applicable.  
 Family 1  Family 2 
 I-1-1 I-1-2 I-2-1 I-2-2  II-1-1 II-1-2 II-2-1 II-2-2 
Age (yrs.) at 
assessment  
82 74 53 53  N/A N/A 43 43 
Sex  Male Female Female Female  Male Female Female Female 
Declared 
Race  
Afro-American  Caucasian 
Psychiatric 
features  
Compulsive 
Personality 
Disorder 
N/A Schizophrenia, 
Paranoid Type, 
onset age 22 
Bipolar I 
Disorder, 
onset age 52 
 Major depression 
and panic disorder 
for 6 months after 
cardiac surgery, 
onset age 73 
N/A Schizoaffective 
Disorder, onset 
age 27 
Single episode 
of Major 
Depression, 
fully remitted, 
onset age 18 
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2.3 Genomic DNA extraction 
Genomic DNA was extracted from white blood cells of all eight participants using the 
PerfectPure DNA Blood Kit (5 Prime, Inc., Gaithersburg, MD, USA) following 
manufacturer protocol. Genomic DNA was extracted prior to the initiation of my 
research.  
2.4. Microarray data generation using the Affymetrix
®
 Genome Wide Human SNP 
Array 6.0 
Genomic DNA was hybridized to Affymetrix
®
 Genome Wide Human SNP Array 6.0 at 
the London Regional Genomics Centre (London, ON) following manufacturer’s protocol. 
Approximately 5 µg of genomic DNA was used from each sample. These data were 
provided to me for this research. 
2.4.1 Affymetrix
®
 Genome-Wide Human SNP Array 6.0 
There are 1.8 million genetic markers represented on the Affymetrix Genome Wide 
Human SNP Array 6.0. Among these, there are more than 906,600 probes testing for 
single nucleotide polymorphisms (SNPs) and more than 946,000 probes for the detection 
of copy number variation.  
Copy number variation probes include: 
i) 5,677 CNV regions from the Database of Genomic Variants 
(http://projects.tcag.ca/variation/) are covered by 202,000 probes. 
ii) 744,000 probes are evenly distributed along the human genome. 
iii) Non-polymorphic copy number probes are included. 
 
iv) Genotyping Console™ (GTC) software, developed by the Broad Institute 
(Boston, MA, USA), is available and uses a high-resolution reference map and 
a copy number polymorphism (CNP)-calling algorithm for the detection of 
CNVs.  
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Single nucleotide polymorphisms (SNPs) probes include: 
i) Unbiased selection of 482,000 SNPs. 
ii) Selection of additional 424,000 SNPs. 
iii) Tag SNPs. 
iv) SNPs from chromosomes X and Y. 
v) Mitochondrial SNPs. 
vi) New SNPs added to the dbSNP database. 
vii) SNPs located in recombination hotspots. 
 
2.5 Selection of packages for Microarray data analysis  
Currently, there are several packages available to analyze microarray data.  For the 
Affymetrix
®
 Genome Wide Human SNP Array 6.0 data, the most commonly used 
packages are (i) Affymetrix Genotyping Console 4.1 (GTC) (Affymetrix, Santa Clara, 
CA, USA), (ii) Partek
®
 Genomics Suite™ (PGS) (Partek Inc., St. Louis, MO)  and (iii) 
PennCNV (Jeanette E Eckel-Passow et. al., 2011).  This study utilized all three packages 
to analyze the same set of raw array data. 
 
2.5.1 Affymetrix
®
 Genotyping Console™ 
The Affymetrix® Genotyping Console™ 4.1 software (GTC) 
(http://www.affymetrix.com/) provides a way to create genotype calls for .cel files. GTC 
generates genotype, copy number and Loss of Heterozygosity (LOH), copy number 
segments data, and copy number variation data for Genome-Wide Human SNP Array 6.0. 
For these analyses, GTC uses Birdseed V2, BRLMM-P+, and Canary algorithms 
respectively. An overview of GTC workflow for the detection of these genomic features 
using array data is shown in Figure 2. 
Before performing analysis of the data generated by the Genome-Wide SNP Array 6.0, 
GTC requires some initial setup, the steps of which are outlined below: 
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i] Creation of new workspace and data set where you can load the microarray data. 
ii] Import the array data into the data set. Input data files are: 
 A] Sample files (.arr/.xml files for each sample) 
 B] Intensity data files (.cel files for each sample) 
iii] Perform the intensity quality control (QC) test for the quality of each sample intensity 
file.  This process allows the determination of the input data quality. GTC has developed 
different control features for this process, including the QC Call Rate matrix and Contrast 
QC matrix: 
a) QC Call Rate matrix: GTC creates a QC call rate matrix table with QC values 
for each sample. Default QC Call Rate Threshold is ≥ 86. This value may be 
changed depending on the user’s requirements. Data in this study were analyzed 
using the default value. Contrast QC matrix: Contrast QC is the QC matrix within 
GTC software. The default threshold is ≥ 0.4 for each sample. It uses 10,000 
random SNPs detected by the Genome-Wide Human SNP Array 6.0 to calculate 
the contrast QC for each sample. 
Depending on the QC value for each sample, GTC places each call into one of three 
groups: All, In Bounds, and Out of Bounds.  
After the initial setup, three different types of analyses can be performed: Genotyping, 
Copy Number and Loss of Heterozygosity (CN/LOH) analysis, and Copy Number 
Variation analysis.  Furthermore, from the CN/LOH analysis we can do Copy Number 
Segment Analysis.  
i. Genotyping: Birdseed’s assign AA, AB, and BB genotype calls for each sample 
with two copies of a SNP, then characterize genotype and allele-specific probe 
responses for each SNP. Birdseed uses normalized and summarized intensities 
from a set of .cel files for each SNP allele. This takes the form of a matrix with N 
columns and 2*M rows, where N is the number of samples to be analyzed, and M 
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is the number of SNPs. It is a 2d Gaussian Mixture Model (GMM) that clusters 
diploid samples into the canonical SNP genotype AA, AB, and BB. 
This analysis creates following results for each SNP probe set for each sample:  
  a) SNP Call Rate 
  b) SNP Call (AA, AB, BB) 
  c) Minor Allele Frequency 
  d) Hardy-Weinberg p-value 
ii. Copy Number & Loss of Heterozygosity: GTC creates Copy Numbers and Loss 
of Heterozygosity using this analysis. Segment analysis then creates the copy 
number segment report, which allows the user to see the chromosomal break 
points and gene overlap for the copy number variation using the GTC browser. 
This analysis creates an output file extension with CN5.cnchp, which contains 
both copy number and loss of heterozygosity values. This analysis can be 
performed in two different ways: 
a) Reference Model File Creation and Analysis (Batch Sample Mode): This mode 
first creates a Reference Model file using the .cel files for the selected samples. 
Then each sample file is compared with this reference file. 
b) Analysis with a Previously Created Reference Model File (Single Sample 
Mode).  
In this analysis, each sample file is compared to a previously created Reference 
Model file. This reference file was created using HapMap270 sample files 
supplied by Affymetrix. 
Both these methods use BRLMM-P+ algorithm for the analysis. Copy number 
segment analysis creates segment data files and segment summary files.  
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iii. Copy Number Variation Analysis: Copy Number Variation (CNV) Analysis 
uses the Canary algorithm to make a CNV state call (0, 1, 2, 3, 4) for copy number 
variations in the genome. A region with copy number variation may contain a few 
or too many CN/SNP probe sets. Canary algorithm was developed by the Broad 
Institute for the purpose of making copy number state calls for genomic regions 
with copy number variations. Canary algorithm identifies regions of known copy-
number variation, especially suited for regions of common variation. Canary is a 
1d Gaussian Mixture Model (GMM). It uses HapMap model file to determine the 
region of known CNV. Another algorithm called Birdseye discovers regions of 
variable copy number, especially those that are rare or de novo. It is a Hidden 
Markov Model (HMM) to find regions of variable copy number in a sample. 
The following support files are necessary to use for all above mentioned data 
analysis in GTC: 
a) Library file sets for genotyping, copy number/LOH/CN segment and copy 
number variation analysis. 
  b) Reference Model files for SNP 6.0 single sample Copy Number/LOH analysis 
  SNP lists (provided by Affymetrix). 
c) Browser Annotation files. 
Using the GTC browser the user is able to observe the copy number analysis results; 
specifically, Genome View, Chromosome Wise View, Segment Report Table, Copy 
Number Variation with Gene Overlap, log2 Ratio values and CN state values for each 
individual.  
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Figure 2: Overview of Affymetrix
®
 Genotyping Console
TM
  workflow 
  
Create or Select a user profiles 
Load Data 
i] Create a workspace & data set(s) 
ii] Add samples (ARR) & intensity data (.cel) to the data set 
 
Perform intensity Quality Control 
Genome-Wide SNP Array 6.0 
Genotyping Copy Number & 
LOH Analysis 
Copy Number Variation Analysis 
Copy Number 
Segment Analysis 
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2.5.2 Partek
®
 Genomics Suite™  
 Partek
®
 Genomics Suite™ (PGS) (http://www.partek.com/) is a software that is capable 
of analyzing SNP-genotyping arrays with closely spaced genomic markers (Affymetrix
®
 
and Illumina
®
), to detect amplified or deleted regions in the genome within and shared 
across samples. An overview of copy number variation analysis in PGS is shown in 
Figure 3. 
PGS uses Affymetrix .cel and CHP files as input data. PGS creates a principal component 
analysis (PCA) scatter plot to visually assess the intensity distribution of the dataset 
including any outliers. By observing the PCA scatter plot we can assess the 
appropriateness of the variation within and between samples. Next, the software estimates 
the number of copies of each marker (allele). For this step, PGS uses a paired and 
unpaired method.  In the paired method, PGS assumes that each sample has its own 
reference sample. In the unpaired design, PGS uses a common reference sample for all 
samples in the dataset. Our data was analyzed using the unpaired method.  Next, the 
software was used to detect regions with copy number variation for each marker, with the 
goal of deriving a list of regions where adjacent markers share the same copy number. 
PGS offers two different algorithms for region (CNV) detection. 
At their core, both algorithms examine trends across multiple adjacent markers. The 
genomic segmentation algorithm identifies breakpoints in the data, changes in copy 
number between two neighbouring regions. This method is used to find segmentation 
according to three criteria:  
i. Criteria one: Neighbouring regions should have statistically significantly 
different average intensity. This is calculated using two-tailed t-test and cut-off p-
value defined by user (default p-value is 0.001).  
ii. Criteria two: Determine breakpoints (region boundary), chosen to give optimal 
statistical significance (as defined by a lower p-value).  
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Figure 3: Overview of Partek
®
 Genome Suite
TM
 workflow 
 
 
 
 
 
 
 
 
 
Import Affymetrix .cel & CHP files 
Create and estimate copy number 
Map break points for copy number 
Detect amplification and deletion 
21 
 
iii) Criteria three: Define the minimum number of genomic markers (with a 
default value of 10) that constitutes a “region”. The HMM algorithm identifies 
discrete changes of whole number copy number states (e.g., 0, 1, 2 … ) and 
attempts to find regions with those numbers of copies. We have used this 
segmentation model for our data analysis.  
Using the above information, the next goal is to determine the amplifications and 
deletions across the genome. Two one-sided t-tests are used to compare the mean copy 
number variation predicted in the region with the expected normal copy number. 
Finally PGS generates an output file entitled “segmentation.txt ” containing the above 
mentioned “all values” for copy number variation. These “all values” are chromosome 
number, start position, stop position, cytoband, and copy number state. This study has 
used this output file for further analysis. 
2.5.3 PennCNV 
PennCNV (http://www.openbioinformatics.org/penncnv/) is a copy number variation 
detection software package that used SNP array data for variation identification. It 
analyses intensity data files from Affymetrix and Illumina arrays and applies the 
PennCNV Hidden Markov Model (HMM) algorithm to identify CNV calls for individuals 
that are different from segmentation-based algorithms. 
PennCNV does not use Affymetrix raw .cel files directly. Affymetrix raw .cel files need a 
data processing protocol that converts it into an intensity file. PennCNV has its own data 
pre-processing protocol called PennCNV-Affy. that converts Affymetrix raw .cel files 
into a signal intensity file. Signal intensity files contain Log R Ratio (LRR) and B Allele 
Frequency (BAF) values that are used by PennCNV for CNV calling. The flowchart in 
Figure 4 is an overview of the PennCNV workflow. 
There are two major steps in PennCNV for calling CNVs within data for an individual. 
Step I: Conversion of raw Affymetrix .cel files into intensity data files 
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Figure 4: Overview of PennCNV workflow. 
 
 
 
 
 
 
Raw .cel files from Affymetrix SNP Arrays 6.0 
Affymetrix Power Tools software 
 Quantile normalization 
 Signal extraction 
 Signal summarization 
 Genotype calling (birdseed) 
Raw signal intensity files 
Genotype call and confidence files 
generate_affy_geno_cluster.pl 
Canonical Genotype clusters 
normalize_affy_geno_cluster.pl 
LRR and BAF calculation 
PennCNV software 
 File splitting 
 CNV detection 
CNV calling 
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The main goal of this step is to generate normalized signal intensity text files from each 
.cel file which can be used subsequently by PennCNV. This step is divided into four sub 
steps:  
i)  Affymetrix Power Tools (APT) is used to generate genotyping calls from the raw .cel 
files using the Birdseed algorithm. For this step, we also need particular library files and 
annotation files for Affymetrix genome-wide 6.0 array.  
ii) Extractions of allele-specific signal values for each SNP probe using APT. Applying 
quantile normalization algorithm generates a signal intensity value for A allele and B 
allele for each SNP probe. PennCNV-Affymetrix package use HapMap samples for 
quantile normalization. For this normalization process, our samples are more comparable 
to each others.     
iii) Generation of canonical clustering information for each SNP and CNV marker called 
generates a genotype clusters file. The PennCNV- Affymetrix package uses annotation 
files that contain marker positions in the hg18 (NCBI build 36) human genome assembly. 
It also uses the sample’s sex information to identify chromosome X and chromosome Y 
markers. The clustering file is also used to calculate Log R Ratio (LRR) and B Allele 
Frequency (BAF) values. 
iv) This software creates Log R Ratio (LRR) and B Allele Frequency (BAF) value files 
for each marker for each individual. These files are used for CNV calling for each 
individual.  
Step II: CNV calling using intensity data files: 
Using Log R Ratio (LRR) and B Allele Frequency (BAF) values, PennCNV gives CNV 
calls for each individual. In this step, PennCNV uses a Hidden Markov Model (HMM) 
algorithm. 
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2.6 Summarizing the findings:  
Using the above mentioned software all samples has been analyzed and results are 
presented as:  
 Chromosome-wise distribution of copy number variations  
 Size-wise of distribution of copy number variations 
 Frequency of copy number variations:  loss (deletion) and gain (duplication) 
 Frequency of de novo copy number variation, of them frequency of Mitotic and 
Meotic CNVs 
 Frequency of inherited copy number variations. 
2.7 Finding the overlap with segmental duplication  
I have used the Database of Genomic Variants (http://projects.tcag.ca/variation/) to 
calculate the overlap between copy number variation and segmental duplication. 
2.8 Comparing different packages result 
Finally, I have made input files, taking all output from different packages, to assess the 
comparison between these files in Affymetrix’s Genotyping Console browser. I have tried 
to compare my results from different packages with different algorithms and have 
presented a comparison of these data using different methods, with the goal of assessing 
the accuracy of the detection of copy number variation algorithms that are commercially 
available.  
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Chapter 3: Results 
In this study I used eight individual’s microarray data for data analysis. Microarray data 
was generated using the Affymetrix Genome Wide Human SNP Array 6.0. The same set of 
microarray data was analysed by three different methods or algorithms. The methods are (i) 
Affymetrix
®
 Genotyping Console
TM
 (GTC), (ii) Partek® Genomics Suite™ (PGS) and (iii) 
PennCNV. All the outcomes from these three methods are presented below. The next step 
was to identify the overlap of outcomes among these three methods. 
3.1 Method one: Genotyping Console 4.1 (GTC) 
In the first method we used Affymetrix analysing package called Genotyping Console. 
These results are described one by one. 
3.1.1 Distribution of CNV among family members according to size  
Table 2 summarizes the size-wise distribution of CNVs for all eight individuals of the two 
families (Figure 1). It was observed that in both families, CNVs of size 100 to 200 kb were 
most common. There are only 3 CNVs identified with sizes less than 100 kb. On the other 
hand only 9 CNVs were greater than 20 Mb (large size). Only one member in the first 
family (I-1-1) has CNVs sized between 10 to 20 Mb. Not surprisingly most CNVs were in 
the range of 100 kb – 200 kb to be followed by 200 kb to 400 kb in every individual. 
Probably the most unusual observation was in II-1-1 who carried 119 CNVs in the rage of 100-
200 kb. 
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Table 2. Distribution of CNVs among family members according to size using GTC 
 
CNV Size 
Family 1 Family 2 
I-1-1 I-1-2 I-2-1 I-2-2 II-1-1 II-1-2 II-2-1 II-2-2 
<=100 kb 0 0 0 0 2 0 0 1 
>100 to 200 kb 17 18 15 20 119 50 24 24 
>200 to 300 kb 11 6 4 10 25 6 13 9 
>300 to 400 kb 5 5 6 5 11 3 1 4 
>400 to 500 kb 2 0 2 2 6 1 1 2 
>500 to 1000 kb 6 2 4 7 7 2 5 2 
>1 to 10 Mb 9 4 5 3 5 2 4 5 
>10 to 20 Mb 5 0 0 0 0 0 0 0 
>20 Mb 3 0 0 0 2 0 2 2 
Total 58 35 36 47 177 64 50 49 
 
Numerical values in each cell of the table indicate how many CNVs of that particular size  
range were observed in that particular individual. Interestingly all eight individuals had an 
average number of CNVs in the range of 35-65, the father in family 2 had exceptionally 
high number of CNVs (177). This exception is characterised by 119 CNVs in this 
individual in this group characterised by a size range group of 100-200kb.  
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3.1.2 Origin of copy number variation across family members  
Gains of CNVs were higher than loss for every individual in both families. Most of the 
CNVs identified were already reported in DGV (http://projects.tcag.ca/variation/) but few 
novel CNVs were also observed (Table 3). Father in family 2 had a large number of (125) 
of CNVs that were gain and also carried 42 novel CNVs.  
3.1.3 Chromosome wise distribution of CNVs 
Table 4 represents chromosome wise distribution of CNVs for all eight individuals 
studied. Interestingly there was no CNV in chromosome number 13 in family 1. The 
unusual exception in this analysis was the father (II-1-1) in family 2 who carries 
approximately 40 CNVs in chromosome 13. In fact this individual had a total of 177 
CNVs that are distributed to a general increase in CNVs in most chromosomes.  
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Table 3. Copy number variation across family members using GTC 
 
CNVs 
Family 1 Family 2 
I-1-1 I-1-2 I-2-1 I-2-2 II-1-1 II-1-2 II-2-1 II-2-2 
No. of Loss 21 6 5 6 52 11 6 4 
No. of Gain 37 29 31 41 125 53 44 45 
Novel (absent in DGV) 1 1 0 2 42 6 1 0 
Present in DGV 57 34 36 45 135 58 49 49 
Total (for the individual) 58 35 36 47 177 64 50 49 
 
Frequency of CNVs which are losses (deletion) or gains (duplication) and characterisation 
as present or absent from The Database of Genomic Variants (DGV).   
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Table 4.  Chromosome wise distribution of CNV using GTC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chromosome specific distribution of de novo (present in twin(s) and absent in parents) and 
inherited (present in at least one parent) CNVs in family 1 and family 2.  Chr. No = 
Chromosome number
Chr No. 
Family 1 Family 2 
I-1-1 I-1-2 I-2-1 I-2-2 II-1-1 II-1-2 II-2-1 II-2-2 
1 4 2 2 2 11 2 6 6 
2 4 2 5 5 11 2 2 3 
3 1 4 2 3 7 4 4 2 
4 4 3 2 4 8 1 3 2 
5 0 0 0 0 12 0 2 1 
6 0 0 0 0 10 2 0 0 
7 2 6 3 4 10 5 3 4 
8 1 0 3 3 7 3 3 3 
9 1 1 2 3 4 4 3 4 
10 2 1 1 1 3 5 1 1 
11 3 1 2 1 5 1 2 2 
12 0 1 0 1 4 3 0 1 
13 0 0 0 0 40 1 1 0 
14 4 6 3 5 4 6 5 3 
15 4 3 1 3 2 6 6 8 
16 2 1 2 3 9 1 1 1 
17 4 1 2 3 8 2 2 1 
18 0 0 0 0 1 0 0 1 
19 0 1 0 0 7 3 2 1 
20 0 0 0 0 0 0 0 1 
21 1 2 2 3 2 3 2 1 
22 3 0 3 2 3 1 1 1 
X 18 0 1 1 9 9 1 2 
Total 58 35 36 47 177 64 50 49 
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3.1.4 De novo CNVs identified with GTC: 
De novo CNVs were defined as those that were not present in parents but present in either 
or both member of twin pairs. Table 5 describes the total number of de novo CNVs 
detected by GTC in twins of family 1 and 2. This method detected 15 CNVs in family 1 
and 25 CNVs in family 2.  Twin 1 in family 1 and 2 had 3 and 8 de novo CNVs 
respectively. Same way twin 2 of both families had 7 and 8 de novo CNVs respectively. 
Both twin share 5 and 9 CNVs in family 1 and 2 respectively. Of these two novel CNVs 
in family 1 in chromosomal position 8q11.21 and 14q32.11 were identified in family 1 
and linked with three genes KIAA0146, PSMC1 and C14orf102. (Appendix Table 1). 
There was only one novel de novo CNV detected in family 2 which was in chromosomal 
location 19q13.41 and in linkage with two genes ZNF331 and DPRX. (Appendix Table 2) 
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Table 5: Identified de novo CNVs using GTC 
 
 
De novo CNV present in Family 1 Family 2 
Twin1 (only) 3 8 
Twin2 (only) 7 8 
Twin1 & Twin2 5 9 
Total 15 25 
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3.1.5 Probe assessment of de novo mitotic CNV in family 1 
Table 6 represents the probe distribution pattern to identify de novo CNVs. There were 10 
de novo CNVs present in only one of the two twins in family 1. Most of the de novo 
CNVs were identified with both SNP and CN probes except two CNVs. CNVs at 
chromosomal locations 8p23.1 and 9p11.2were detected with CN probes only (asterisk in 
the first column). Identified CNVs had more CN probes than SNP probes. CNV at 
14q32.11 contain 32 SNP probes and 27 CN probes on that region. The signals at those 
probes had allowed identification of gains/losses listed in the table. 
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Table 6: Probe distribution across the de novo mitotic CNV region in Family 1 
Sl. No. 
Present 
in 
CNV 
Position 
Status 
# of 
Total 
Probe 
# of 
SNP 
Probe 
# of 
CN 
Probe 
1 I-2-1 1p36.13 Gain 24 2 22 
2 I-2-2 4q28.3 Gain 45 11 34 
3* I-2-1 8p23.1 Loss 23 0 23 
4 I-2-2 8q11.21 Loss 35 5 30 
5* I-2-1 9p11.2 Gain 19 0 19 
6 I-2-2 9p13.1 Gain 12 3 9 
7 I-2-2 9q12 Gain 11 4 7 
8 I-2-2 12p13.31 Gain 79 24 55 
9 I-2-2 14q32.11 Loss 59 32 27 
10 I-2-2 21q11.2 Gain 59 11 48 
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3.1.6 Distribution of probes used to detect CNVs and number of probe signals those 
agreed with loss or gain calls in family 1  
 Figure 5 is the graphical presentation of the distribution of probes those were used in 
Affymetrix array to detect CNV (black bar) and the number of probes that followed the 
expected pattern of de novo CNVs (grey bar). The table underneath of the chart shows the 
percentage of the probes that satisfies the presence of CNVs along with chromosomal 
location. This is a graphical presentation of Table 6. It was interesting to observe that 
except one CNV at 1p36.13, all other CNVs were detected by more than 50% of the 
probes used. 
 
3.1.7 Graphical representation of probe intensity in log2 ratio for family 1 
The following line charts graphically presents the gain or loss of particular CNV present 
in one twin but absent from co-twin. Two line charts (Figure 6 (a) and (b)) represent the 
log2 ratio intensity values of each probe in the twin sample at the chromosomal locations 
8p23.1 and 9p13.1 respectively. The chart represents the probe intensity values for loss 
and gain of CNVs in twin two in family number 1. The line charts characterised by black 
continuous lines represent the probes intensity for twin (I-2-1) with either loss or gain of 
copy number variation and light dotted line represent co-twin (I-2-2) probe intensity 
value.  
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Location 1p36.13 4q28.3 8p23.1 8q11.21 9p11.2 9p13.1 9q12 12p13.31 14q32.11 21q11.2 
Percent 33.33 55.56 82.61 74.29 57.89 75 63.64 59.49 52.54 61.02 
 
Figure 5: Graphical representation of the distribution of total number of probes used to detect CNVs and number of probe 
signals that agreed with loss or gain calls in family 1 
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8p23.1 – Loss (continuous line) 
 
           
Figure 6(a): Pattern of distribution of the log2 ratio between twins for a loss of CNV. Dotted line represents data for twin 2 
and continuous line represents data for twin 1 with loss of CNV. 
9p13.1 – Gain (continuous line) 
 
      
Figure 6(b): Pattern of distribution of Log2 ratio between twins for a gain of CNV. Dotted line represents data for twin 1 and 
continuous line represents data for twin 2 with gain of CNV. 
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3.1.8 Probe assessment of de novo mitotic CNV in family 2 
Table 7 represents the probe distribution pattern used to detect de novo CNVs in family 2.  
There were 16 (present only one twin) de novo CNVs in family 2, identified with several 
copy number (CN) and single nucleotide change (SNP) probes. Most of the de novo 
CNVs were identified with both SNP and CN probes except one CNV. CNVs at 
chromosomal locations 15q13.2 were detected with CN probes only (asterisk in the first 
column). All identified CNVs had more CN probes than SNP probes (almost twice) 
excluding one CNV (15q13.1). 
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Table 7: Probe distribution across the de novo mitotic CNV region in Family 2 
Sl. No. 
Present 
in 
CNV 
Position 
Status 
# of 
Total 
Probe 
# of 
SNP 
Probe 
# of 
CN 
Probe 
1 II-2-2 1q21.1 Gain 29 1 28 
2 II-2-2 1q43 Gain 15 4 11 
3 II-2-1 3q21.2 Gain 61 16 45 
4 II-2-1 4p11 Gain 10 2 8 
5 II-2-1 5p13.3 Gain 41 9 32 
6 II-2-1 7q11.21 Gain 44 1 43 
7 II-2-2 7q35 Gain 22 1 21 
8 II-2-2 9q12 Gain 14 2 12 
9 II-2-2 12p13.31 Gain 76 24 52 
10 II-2-1 13q11 Gain 83 24 59 
11 II-2-2 15q11.1 Gain 21 2 19 
12 II-2-2 15q13.1 Gain 41 21 20 
13* II-2-1 15q13.2 Gain 16 0 16 
14 II-2-1 17p11.1 Gain 27 4 23 
15 II-2-1 19q13.41 Gain 76 25 51 
16 II-2-2 20q11.1 Gain 23 6 17 
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3.1.9 Distribution of probes used to detect CNVs and number of probe signals those 
agreed with loss or gain calls in family 2 
The following chart is the graphical presentation of Table 5. Figure 7 presents the 
distribution of probes that were used in Affymetrix array to detect CNV (black bar) and 
the number of probes that agree or confirm the presence of that particular CNV (grey 
bar). The attached table represents the percentage of the same probe distribution that 
satisfies the presence of CNVs along with chromosomal location. It was interesting to 
observe that each CNV had been detected by more than 44% of the probes. 
3.1.10 Graphical representation of probe intensity in log2 ratio: 
The following line chart (Figure 8 (a) and (b)) is the graphical presentation of gain or loss 
of particular CNV present in one twin but absent from co-twin. Two line charts 
representing the log2 ratio value of each probe present in copy number variation in one 
twin sample which located at chromosomal locations 5p13.3 and 7q11.21 respectively. 
Both were gain of copy number variations present in one twin (I-2-1) between 
monozygotic twin pair and represented in black continuous line whereas light dotted line 
represent co-twin (I-2-2) probe intensity value. This graph supports the presence of gain 
of copy number variation depending of log2 ration intensity value. 
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Figure 7: Probe frequencies and percent of probes that support the loss or gain in de novo CNVs in family 2 
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5p13.3 – Gain (Continuous line) 
    
Figure 8(a): Pattern of distribution of the log2 ratio between twins in family 2. Dotted line represents data for twin 2 and 
continuous line represents data for twin 1 with gain of CNV. 
7q11.21 – Gain (Continuous line) 
    
Figure 8(b): Pattern of distribution of Log2 ratio between twins in family 2. Dotted line represents data for twin 2 and 
continuous line represents data for twin 1 with gain of CNV.
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3.1.11 Inherited CNV 
Table 8 summarises the exact number of inherited CNVs in twins of both families. The 
table describes the pattern of inheritance or the number of CNVs twins inherited 
exclusively from either father or mother or from both parents. The later does not carry 
much information since those CNVs were common to all members in the family. It was 
interesting to observe that twin 1 in family 1 and twin 2 in family 2 inherited their CNVs 
exclusively from father. The overlapped genes with these CNVs are described in 
Appendices tables 3 and 4 for family 1 and 2 respectively. 
 
3.1.12 Summary of GTC analysis 
1. Frequencies of CNVs for individuals in two monozygotic twin families were 
between 35 and 64 (except one individual). 
2. Most of the CNVs were of size range 100 and 200 kb. 
3. CNVs were distributed over all whole genome (chromosomes, 1 to X) for all 8 
individuals. 
4. Observed CNVs were more gain than loss in all members. 
5. Twin did not inherit identical CNVs from parents in both families and most of the 
de novo CNVs are present only in one twin.  
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Table 8: Inherited CNV using GTC 
 
 Family 1 Family 2 
Inherited in 
Father  
(only) 
Mother 
(only) 
Father  
&  
Mother 
Father  
(only) 
Mother 
(only) 
Father  
&  
Mother 
Twin1 (only) 2 0 0 2 3 1 
Twin2 (only) 2 2 2 3 0 1 
Twin1 & Twin2 8 6 11 11 4 10 
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3.2 Method two: Partek
®
 Genome Suite
TM
 (PGS) 
In the second method we used PGS for the CNV analysis for same eight individual’s data 
from two families. All outcomes were tabulated below. 
3.2.1 Size wise distribution of CNVs among family members  
Table 9 represents the size distribution of CNVs detected by PGS in all eight individuals 
in family 1 and 2. It was interesting to observe that PGS can detect large (>500kb -20 
Mb) CNVs. CNV of size less than 500 kb was almost absent in both families. Father of 
family 2 had exceptionally large number of CNVs characterised by 198 CNVs of size 10-
20 Mb and 541 CNVs of size more than 20 Mb. The Mother of the same family also had 
113 CNVs of size more than 20 Mb.  
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Table 9: Size distribution of CNV using PGS 
 
 
   
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CNVs Size 
Family 1 Family 2 
I-1-1 I-1-2 I-2-1 I-2-2 II-1-1 II-1-2 II-2-1 II-2-2 
<=100 kb 0 0 0 0 0 0 0 0 
>100 to 200 kb 0 0 0 0 0 0 0 0 
>200 to 300 kb 0 0 0 0 0 0 0 0 
>300 to 400 kb 0 0 0 0 0 0 0 0 
>400 to 500 kb 0 0 0 0 0 0 0 0 
>500 to 1000 kb 0 0 1 0 1 1 1 1 
>1 to 10 Mb 26 22 16 15 31 31 17 22 
>10 to 20 Mb 14 10 14 15 198 40 8 13 
>20 Mb 24 17 24 21 541 113 30 29 
Total 64 49 55 51 771 185 56 65 
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3.2.2 Origin of copy number variation across individual family members  
Table 10 represents origin of CNVs identified in all family members of family 1 and 2. 
Interestingly PGS detected higher gains of CNVs in father and mother of family 2; in 
them, the father contained 691 and mother contained 134 CNVs respectively. 
 
3.2.3 Chromosome wise distribution of CNVs 
Table 11 represents chromosome wise distribution of CNVs in all eight individuals of family 1 
and 2. PGS detected almost same number of CNVs in all individuals except in family 2 where the 
father contained exceptionally high number of CNVs (771) and the mother had 185 CNVs. 
Another observation was that the father of the same family contained 54 CNVs only in 
chromosome X which were significantly more than any other individual in both families.  
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Table 10: Copy number variation across family members using PGS 
 
CNVs 
Family 1 Family 2 
I-1-1 I-1-2 I-2-1 I-2-2 II-1-1 II-1-2 II-2-1 II-2-2 
No. of Loss 39 35 33 27 80 51 36 46 
No. of Gain 25 14 22 24 691 134 20 19 
Total (for the individual) 64 49 55 51 771 185 56 65 
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Table 11: Chromosome wise CNV distribution using PGS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chr 
No. 
Family 1 Family 2 
I-1-1 I-1-2 I-2-1 I-2-2 II-1-1 II-1-2 II-2-1 II-2-2 
1 3 6 8 8 62 19 5 6 
2 5 2 6 4 66 15 5 6 
3 8 4 4 4 53 9 3 3 
4 7 5 6 6 54 10 4 6 
5 1 5 4 4 45 16 4 3 
6 4 2 2 1 51 17 6 7 
7 3 3 3 3 38 10 2 3 
8 4 5 4 4 45 12 2 5 
9 2 1 1 2 33 3 1 0 
10 2 1 3 2 40 10 2 4 
11 2 1 2 2 31 5 3 4 
12 4 3 1 1 38 12 3 2 
13 1 0 1 2 38 5 1 1 
14 0 2 2 2 23 8 2 1 
15 3 2 1 1 18 7 1 1 
16 3 1 1 1 23 7 3 2 
17 2 2 0 0 15 2 1 1 
18 1 1 2 0 16 1 1 1 
19 0 1 1 0 10 1 1 2 
20 0 0 0 0 12 6 2 2 
21 0 0 0 0 7 1 0 0 
22 2 1 1 1 2 5 1 3 
X 7 1 2 3 51 4 3 2 
Total 64 49 55 51 771 185 56 65 
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3.2.4 De novo CNVs identified with PGS 
Table 12 describes the total number of de novo CNVs detected by PGS in twins of family 
1 and 2. Twin 1 of both families had 6 de novo CNVs exclusive to them; on the other 
hand twins of family 1 had 4 and in family 2, 12 CNVs respectively. Both twins shared 
14 and 11 CNVs in family 1 and 2 respectively. Out of 24 in family 1 and 29 in family 2 
there were few known genes mapped near or within the CNVs of both families 
(Appendices Table 5 and 6). 
 
3.2.5 Inherited CNVs identified using PGS 
Table 13 describes the pattern of inheritance and total number of inherited CNVs in eight 
individuals of family 1 and 2.  The pattern of inheritance detected by PGS was quite 
different. This method detected twin 2 of family 1 and twin 1 in family 2 inherited their 
CNVs exclusively from father and mother respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12: Identified de novo CNVs using PGS 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
De novo CNV present in Family 1 Family 2 
Twin1 (only) 6 6 
Twin2 (only) 4 12 
Twin1 & Twin2 14 11 
Total 24 29 
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Table 13: Identified inherited CNVs using PGS 
 
 Family 1 Family 2 
Inherited in 
Father  
(only) 
Mother 
(only) 
Father  
&  
Mother 
Father  
(only) 
Mother 
(only) 
Father  
&  
Mother 
Twin1 (only) 2 1 0 0 2 0 
Twin2 (only) 2 0 0 1 1 1 
Twin1 & Twin2 12 9 2 12 18 5 
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3.2.6 Summary of PGS analysis 
1. Almost in all individuals except two, frequencies of CNVs were between 35 and 
64. 
2. PGS detected CNVs of larger size (>1 Mb) in all individuals. Smaller size CNVs 
were almost absent.  
3. Detected CNVs were distributed in whole genome (chromosomes, 1 to X) for all 8 
individuals. 
4. There were more losses than gains of CNVs in all family members. 
5. Twin did not inherit identical CNVs from parents in both families and de novo 
CNVs observed in twins varied significantly from co-twin.  
 
3.3 Method three: PennCNV 
In the third method we use PennCNV.  The same raw data were analysed by PennCNV and 
results are tabulated below.  
 
3.3.1 Distribution of CNVs among family members according to size 
Table 14 represents the size wise distribution of CNVs in all eight individuals of family 1 and 2. 
Like PGS, PennCNV also detected drastically higher number of CNVs of size 1-20 Mb. Very few 
CNVs of size range 200-1000 kb were detected. With this method as well father in family 2 had 
very large number (131) of CNVs of size more than 20 Mb. All other individuals carried total 
number CNVs of range 31-49. 
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Table 14: Size distribution of CNV using PennCNV 
 
CNVs Size 
Family 1 Family 2 
I-1-1 I-1-2 I-2-1 I-2-2 II-1-1 II-1-2 II-2-1 II-2-2 
<=100 kb 0 0 0 0 0 0 0 0 
>100 to 200 kb 0 0 0 0 0 0 0 0 
>200 to 300 kb 0 0 0 0 0 1 0 0 
>300 to 400 kb 1 0 1 1 2 0 1 2 
>400 to 500 kb 0 0 0 1 0 0 0 0 
>500 to 1000 kb 0 0 0 0 0 0 1 1 
>1 to 10 Mb 17 13 10 11 10 13 14 17 
>10 to 20 Mb 3 3 4 3 35 3 3 4 
>20 Mb 23 18 16 14 161 32 12 15 
Total 44 34 31 30 208 49 31 39 
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3.3.2 Origin of copy number variation across family members  
Table 15 summarises the origin of CNVs in all members of family 1 and 2. Gain or loss 
of CNVs detected with PennCNV was almost similar in all members of both families 
except the father in family 2. This observation was characterised by 66 losses and 142 
gains of CNVs. Twin 1 of family 2 also had more loss of CNVs (22) than gain (9). 
 
3.3.3 Chromosome wise distribution of CNVs 
Table 16 summarises the chromosome wise distribution of CNVs obtained with PennCNV 
analysis. Like GTC, PennCNV also detected on exceptionally higher number (49) of CNVs 
in chromosome 13 in the father of family 2. Another interesting observation is that 
PennCNV does not identify any CNV in the X chromosome for any member of both 
families.   
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Table 15: Copy number variation across family members using PennCNV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CNVs 
Family 1 Family 2 
I-1-1 I-1-2 I-2-1 I-2-2 II-1-1 II-1-2 II-2-1 II-2-2 
No. of Loss 21 11 14 18 66 29 22 29 
No. of Gain 23 23 17 12 142 20 9 10 
Total (for the individual) 44 34 31 30 208 49 31 39 
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Table 16: Chromosome wise CNV distribution using PennCNV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chr No. 
Family 1 Family 2 
I-1-1 I-1-2 I-2-1 I-2-2 II-1-1 II-1-2 II-2-1 II-2-2 
1 8 3 4 5 14 8 3 3 
2 3 3 4 3 13 3 2 2 
3 4 5 2 3 10 3 1 1 
4 8 1 3 3 12 2 2 4 
5 0 5 2 2 13 4 0 1 
6 1 0 0 0 11 4 4 6 
7 2 2 4 3 16 3 3 3 
8 2 2 2 3 10 2 2 4 
9 1 1 1 0 10 1 0 0 
10 0 0 1 0 10 3 1 1 
11 2 2 2 3 5 2 2 2 
12 3 2 0 0 8 1 1 0 
13 1 0 0 0 49 0 1 1 
14 1 2 2 1 6 2 1 2 
15 3 1 1 2 5 2 1 1 
16 2 0 2 1 3 3 2 2 
17 1 2 0 0 3 2 0 0 
18 1 1 0 0 1 0 1 1 
19 0 1 0 0 1 2 3 2 
20 0 1 0 0 5 2 1 2 
21 0 0 0 0 2 0 0 0 
22 1 0 1 1 1 0 0 1 
X 0 0 0 0 0 0 0 0 
Total 44 34 31 30 208 49 31 39 
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3.3.4 De novo CNVs 
Table 17 describes the total number of de novo CNVs detected by PennCNV in twins of 
family 1 and 2. Twin 1 of both families had 3 and 2 de novo CNVs exclusively and twin 2 
of both families had 4 and 8 CNVs respectively. Both twins shared 6 and 7 CNVs in 
family 1 and 2 respectively. Out of 13 in family 1 and 17 in family 2 there were few 
known genes mapped near or in the CNVs of both families (Appendices Table 9 and 10). 
CNV in 8p23.1 in twin 2 of family 2 contain exceptionally high number of gene of beta 
defensin (DEFB) family (Appendix Table 10). 
 
 
3.3.5 Inherited CNVs identified with PennCNV 
Table 18 summarises the total number of inherited CNVs and their pattern of inheritance 
in both families. Like method 2, PennCNV also detected that twin 2 in family 1 and twin 
1 in family two inherited their CNVs from corresponding father and mother. 
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Table 17: Identified de novo CNVs using PennCNV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De novo CNV present in Family 1 Family 2 
Twin1 (only) 3 2 
Twin2 (only) 4 8 
Twin1 & Twin2 6 7 
Total 13 17 
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Table 18: Identified inherited CNVs using PennCNV 
 
 
 Family 1 Family 2 
Inherited in 
Father  
(only) 
Mother 
(only) 
Father  
&  
Mother 
Father  
(only) 
Mother 
(only) 
Father  
&  
Mother 
Twin1 (only) 4 1 0 1 0 0 
Twin2 (only) 2 0 0 2 1 0 
Twin1 & Twin2 5 7 4 8 12 0 
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3.3.6 Summary of PennCNV analysis 
1. Observed frequencies of CNVs in all individuals range from 35-64 except one 
individual.  
2. PennCNV detected CNVs of larger size (>1 Mb) in all individuals. Smaller size 
CNVs were almost absent.  
3. PennCNV was unable to detect any CNV in X chromosome.  
4. This method detected almost equal loss and gain of CNVs in all individuals. 
5. Twin did not inherited identical CNVs from parents in both families and de novo 
CNVs observed in twin varied significantly from co-twin.  
3.4 Comparison of CNV results obtained with three different methods: 
Data generated and analysed with Affymetrix platform were reanalysed with multiple 
methods in order to 
I) validate the results of Affymetrix® Genotyping ConsoleTM 
II) identify any new structural variation 
III) compare the similarities and dissimilarities among three CNV calling 
algorithms 
3.4.1 Frequency of copy number variations using three different packages  
Same raw data were analysed with three different packages GTC, PGS and PennCNV. 
The total numbers of CNVs obtained with each packages for all individuals were 
tabulated in Figure 9(a) and 9(b). It was interesting to observe that total number of CNVs 
obtained with PGS scored maximum and with PennCNV scored minimum in all cases 
except individual II-1-1 in family 2. 
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Figure 9(a): Total number of copy number variation identified by three different CNV 
calling algorithms for all family members of family 1. Purple, olive and orange color bar 
represents data originated by GTC, PGS and PennCNV respectively.  
 
 
 
62 
 
 
 
Figure 9(b): Total number of copy number variation identified by three different CNV 
calling algorithms for all family members of family 2. Purple, olive and orange color bar 
represents data originated by GTC, PGS and PennCNV respectively. 
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3.4.2 Comparison of percent distribution of Gain and Loss of CNV  
Comparison of percentage of gain and loss of copy number variation for each individual 
in two families (Figure. 10(a) and (b)) represented in bar carts within pedigree.  It was 
interesting to observe that gain of CNVs was maximally detected with GTC compared to 
PGS and PennCNV.  
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Figure 10(a) : Percentages of gains and losses of CNVs obtained by three different CNV 
calling algorithms in family 1. Blue represents gain and red represents loss of CNV. 
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Figure 10(b) : Percentages of gains and losses of CNVs obtained with three different 
CNV calling algorithms in family 2. Blue represents gain and red represents loss of CNV. 
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3.4.3 Size distribution of copy number variations identified with different algorithms 
for each individual 
Size of CNVs identified with different algorithms or packages differ significantly from 
each other. It was interesting to observe that both in family 1 (Figure 11(a)) and family 2 
(Figure 11(b)), in all individuals, CNV of large size (1-20mb) were identified mostly by 
PGS and PennCNV; on the other hand smaller CNV (100-500 kb) identified significantly 
by GTC. 
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Figure 11(a): Size distribution of copy number variations identified with three different 
algorithms for each individual in family 1 presented in pedigree. 
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Figure 11(b): Size distribution of copy number variations identified with three different 
algorithms for each individual in family 2 presented in pedigree 
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3.5 Summary of CNVs identified with three different methods: 
It was important to list any exclusive CNV identified with any particular package, or 
CNV identified with more than one package.  Later CNVs are very crucial because they 
were captured with multiple softwares. 
3.5.1 Summary of results in family 1: 
Total, shared and exclusive number of de novo and inherited CNVs are presented with 
Venn diagram (Figure 12) and tabulated in Table 19. In total six CNVs which are 
approximately 14 percent were confirmed by all packages. 
Table 19 is the list of 6 CNVs commonly identified by all three methods for family 1. All 
CNVs excluding (2p11.2) were overlapped with genomic regions. All these were 
inherited CNVs. 
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Figure 12: Venn diagram showing exclusive and overlapped CNVs identified with 
Affymetrix, Partek and PennCNV in family 1. Shared CNVs are shown in overlapped 
portion of diagram. 
 
 
 
 
 
 
 
1 
15 
Affymetrix Partek 
PennCNV 
15 
36 
3 
29 
6 
71 
 
 
 
 
 
 
 
Table 19: Common CNVs identified by three methods for family 1 
Sl. No. 
Affymetrix-Partek-PennCNV 
Location Gene 
1 2p11.2  
2 7q11.21 INTS4L1, ZNF92 
3 8p23.1 
LOC349196, DEF109P1B, DEFB103A, DEFB103B, 
SPAG11B, DEFB104B, DEFB104A, DEFB106B, DEFB106A, 
DEFB105B, DEFB105A, DEFB107A, DEFB107B, FAM90A7, 
SPAG11A, DEFB4, FAM66E, DEF109P1B 
4 11p15.4 OR51A4, OR51A2 
5 14q32.33 KIAA0125, ADAM6 
6 22q11.21 
RIMBP3C, RIMBP3B, HIC2, PI4KAP2, RIMBP3C, UBE2L3, 
POM121L8P 
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3.5.2 Summary of results in family 2: 
Like family 1, total, shared and exclusive number of de novo and inherited CNVs scored 
with three different packages are presented with Venn diagram (Figure 16). Six CNVs 
which is around 11 percent were common to all packages in family 2. 
Table 20 represents the list of 6 CNVs commonly identified by all three methods for 
family 2. First CNV (5p13.3) in the table was a de novo but rest were inherited CNVs. All 
of them were overlapped with genic regions. 
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Figure 13: Venn diagram showing exclusive and overlapped CNVs identified with 
Affymetrix, Partek and PennCNV in family 2. Shared or commonly identified CNVs are 
shown in overlapped Venn diagrams.  
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 Table 20: Common CNVs identified by three methods for family 2 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Sl. No. 
Affymetrix-Partek-PennCNV 
Location Gene 
1 5p13.3 PDZD2, GOLPH3 
2 1p21.1 
AMY2B, LOC648740, AMY2A, 
AMY1A, AMY1C, AMY1B 
3 3q12.2 GPR128, TFG 
4 11p15.4 LOC650368, OR51A4, OR51A2 
5 14q32.33 KIAA0125, ADAM6 
6 15q25.3 AKAP13 
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3.5.3 Comparison between two families  
This study identified six copy number variations those were confirmed by all the three 
methods for both families. One more interesting observation was that among these six 
CNVs, there were two common CNVs found in both families and both were inherited 
CNVs (Table 21). In family 1, CNV (11p15.4) were overlapped with gene region and 
common to all family members. That means this CNV was inherited from both parents to 
both twin pairs. But in case of family 2, it was inherited only from father to both twins. 
The second CNV (14q32.33) was also overlapped with the gene region and present in all 
family members for the both families.  
Table 22 describes gene functions of the commonly identified gene for both families. 
Except olfactory receptor family 51 genes (OR51A2 and OR51A4) all other were pseudo 
genes. 
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Table 21: Common CNV identified in two families 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl. No. 
Affymetrix-Partek-PennCNV 
Location Gene 
1 11p15.4 LOC650368, OR51A4, OR51A2 
2 14q32.33 KIAA0125, ADAM6 
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Table 22: Functions of genes located in commonly identified CNVs 
 
 
 
 
 
 
 
 
 
Gene Name Gene Function 
OR51A2 and OR51A4 
(olfactory receptor, family 
51, subfamily A, member 2 
and 4) 
 
Olfactory receptors are responsible to initiate a 
neuronal response that triggers the perception of a 
smell. The olfactory receptor proteins are members 
of G-protein-coupled receptors (GPCR) family and 
encoded by single coding-exon. Olfactory receptors 
are trans membrane and are responsible for the 
recognition and G protein-mediated transduction of 
odorant signals. The olfactory receptor gene family 
is the largest in the genome.  
LOC650368 (asparagine-
linked glycosylation 1-like 
pseudogene),  
KIAA0125,  
ADAM6 (ADAM 
metallopeptidase domain 6, 
pseudo gene) 
Pseudo genes 
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3.6 A special observation 
Interestingly only family number 2 has loss of CNV in chromosome 13 in ‘q’ arm. The 
distribution of the CNV including start and end point is presented in the tables (Table 23, 
24 and 25). This deletion ranges the genomic region between 13q14.2 to 13q21.33.  All 
three different methods (GTC, PGS and PennCNV) were able to identify these CNV 
deletions. But number and size of CNVs identified with PGS differed from rest two 
methods. First and third methods results were more or less same. Affymetrix and Partek 
identified 38 and 39 loss of CNVs respectively in the genomic region. They had some 
difference of CNV sizes. On the other hand second method covered the same genomic 
region with only 3 large size CNVs losses. A graphical comparison of this deletion 
among three methods is shown in figure 14. Detailed information about the CNVs was 
listed in the tables 23, 24 and 25 respectively for three different methods. 
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Table 23: Identity of CNV present in chromosome 13 in father of family 2 using 
GTC 
Sl. 
No. 
Start 
Position 
End 
Position Size(kb) Loss/Gain 
1 47237551 47666738 429 Loss 
2 48148998 48696505 548 Loss 
3 48751953 49312876 561 Loss 
4 49343727 51639572 2296 Loss 
5 52437155 52763266 326 Loss 
6 52826196 52932732 107 Loss 
7 53057893 53192116 134 Loss 
8 53256041 53590407 334 Loss 
9 54680266 54790556 110 Loss 
10 54935168 55098944 164 Loss 
11 55750401 55874339 124 Loss 
12 55974036 56272375 298 Loss 
13 56398440 56585146 187 Loss 
14 56708289 56827502 119 Loss 
15 56934307 57038858 105 Loss 
16 57282053 57980283 698 Loss 
17 58340087 58443546 103 Loss 
18 58676802 58970079 293 Loss 
19 59126155 59350332 224 Loss 
20 59419017 59781724 363 Loss 
21 60075937 60201120 125 Loss 
22 60685046 61083734 399 Loss 
23 61379792 61483739 104 Loss 
24 61650921 61897775 247 Loss 
25 62086051 62225287 139 Loss 
26 62279951 62386580 107 Loss 
27 63059363 63205520 146 Loss 
28 63386740 63794997 408 Loss 
29 63956144 64073049 117 Loss 
30 64177520 64483758 306 Loss 
31 64835495 65128868 293 Loss 
32 65196691 65485151 288 Loss 
33 65671222 66142551 471 Loss 
34 66444238 66561990 118 Loss 
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Table 23 (cont’d) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 66767856 67064534 297 Loss 
36 67105010 67226610 122 Loss 
37 67389818 67536058 146 Loss 
38 67647031 67858955 212 Loss 
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Table 24: Identity of CNV present in chromosome 13 in father of family 2 using PGS 
 Sl. No. Start Position End Position Size(kb) Loss/Gain 
1 49489783 50379977 890194 Loss 
2 50379977 67073644 16693667 Loss 
3 67094698 68375606 1280908 Loss 
 
 
 
 
 
 
 
 
 
82 
 
Table 25: Identity of CNV present in chromosome 13 in father of family 2 using 
PennCNV 
Sl. No. Start Position End Position Size(kb) Loss/Gain 
1 47819459 47951563 132 Loss 
2 48465537 48669985 204 Loss 
3 49049927 50068586 1019 Loss 
4 50070025 50100433 30 Loss 
5 50103430 50495232 392 Loss 
6 50648626 50708007 59 Loss 
7 50728714 51227759 499 Loss 
8 51337276 51377929 41 Loss 
9 52307395 52386159 79 Loss 
10 52510619 52701944 191 Loss 
11 53265283 53335594 70 Loss 
12 53454796 53501480 47 Loss 
13 53672584 53733768 61 Loss 
14 54841867 55045560 204 Loss 
15 55207842 55221845 14 Loss 
16 55756707 56740628 984 Loss 
17 56893714 57553306 660 Loss 
18 57801407 57941247 140 Loss 
19 58340099 58603660 264 Loss 
20 58799930 58923940 124 Loss 
21 60107596 60180155 73 Loss 
22 60731828 61245543 514 Loss 
23 61290320 61476014 186 Loss 
24 61675048 61776378 101 Loss 
25 62278487 62386592 108 Loss 
26 62604846 62642623 38 Loss 
27 63060191 63153394 93 Loss 
28 63395249 63829212 434 Loss 
29 63913286 64065226 152 Loss 
30 64204974 64696387 491 Loss 
31 64835507 65055390 220 Loss 
32 65106479 65301715 195 Loss 
33 65344417 65551994 208 Loss 
34 65724319 65991852 268 Loss 
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Table 25 (cont’d) 
35 66315311 66399797 84 Loss 
36 66592236 66738575 146 Loss 
37 66836797 67056831 220 Loss 
38 67114843 67497129 382 Loss 
39 67568305 67858955 291 Loss 
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Figure 14: Graphical representation from Genotyping Console Browser identifying the 13q deletion for father of family 2 with 
three different methods. From the top, first one was identified by GTC, second one with PGS and bottom last one with 
PennCNV.   
GTC 
PGS 
PennCNV 
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Chapter 4: Discussion  
4.1 Summary 
The identification and characterization of genetic differences across individuals 
represents the next major challenge in human biology. This is currently being attempted 
using two sets of results, those from DNA microarrays and complete genome sequences. 
In both cases, it has proved easier to generate the data than to make sense of the results. In 
this research, I have attempted to assess the analytical challenges associated with the 
generation of whole-genome DNA microarray data. Specifically, I have tested three 
commonly used methods (Affymetrix
®
 Genotyping Console
TM
, Partek
®
 Genome Suite
TM
 
and PennCNV) for their ability to accurately and reliably detect copy number variation 
from array data generated by the Affymetrix
®
 Genome-Wide Human SNP Array 6.0. 
The dataset used in this analysis assesses three degrees of genetic relatedness: unrelated 
individuals representing two different families, first degree relatives representing parents 
and offspring, and monozygotic twin pairs. The results obtained have offered a number of 
conclusions, discussed below. 
1. In addition to single nucleotide differences such as SNPs, copy number variations 
(CNV) contribute to significant genetic variation across individuals: 
 
a) Familial distribution of copy number variation: 
The number of CNVs per individual in both families analyzed ranges from 35 to 
65 variations, with the exception of one individual who is described later. This is 
similar to the number of CNVs per subject reported from many other studies that 
have used the Affymetrix
®
 Genome-Wide Human SNP Array 6.0 (Ku et. al., 
2010). This range is also comparable with the number of CNVs found in Venter’s 
genome (62), established using his complete genome sequence (Levy et. al., 
2007). Most CNVs identified were in the range of 100 to 200 kb, also consistent 
with the size distribution of CNVs reported in the literature (Ku et. al., 2010). The 
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majority of CNVs observed were copy number gains (78.5%).  Further, the 
chromosomal distribution of CNVs was comparable across individuals with the 
exception of the father in family 2 who had consistently higher CNVs that 
affected most of this individual’s chromosomes. Further, more than 50 percent of 
the identified CNVs overlapped with known RefSeq genes. 
 
b) Genetic difference between monozygotic twins: 
This study has been able to establish genome-wide copy number variations (CNV) 
as exist between monozygotic twins that are discordant.  
The monozygotic twins in both families genetically differ from each other via 
different forms of the structural variations. The CNVs present in the monozygotic 
twins were classified into two groups, de novo and inherited. The monozygotic 
twins in family 1 share only 33 percent de novo CNV as compared to her co-twin, 
while the twins in family 2 share 36 percent. This study also observed inherited 
CNV differences between monozygotic twins for the both families. The twins in 
family 1 show more than 9 percent inherited CNVs that they do not share with 
their co-twin and, in family 2, nearby 8.5 percent of their inherited CNVs differ.  
Interestingly, the inherited patterns of CNVs for both twins were not same for 
both families. In family 1, twin one inherited 37%, 22% and 41% CNVs from her 
father (exclusively), mother (exclusively), and both parents respectively, but twin 
two inherited 32%, 26% and 42% respectively. In family two these numbers are 
42%, 23% and 35% for twin one and 48%, 14% and 38% for twin two 
respectively. This study suggests that discordant monozygotic twins also vary 
genetically from each other, data which is supported by recent other studies 
(Bruder et. al., 2008). 
c) De novo events may contribute the individual differences  
A novelty of this study is that we were able to classify observed CNVs into two 
groups based on their absence or presence in one of the parents. CNVs that were 
found in one or both twins and not seen in either parent were classified as de novo.  
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If a de novo CNV was present in both twins, it was considered to have originated 
during meiosis or parental development and when present in only one of the two 
twins, it was assumed to have originated in mitosis during development. This 
classification allowed us to identify 15 and 25 de novo CNVs in family 1 and 
family 2 respectively. The results include the genomic locations as well as 
individual-specific break points, which allow for the assessment of regions of 
overlap that have been previously reported in the Database of Genomic Variants 
(Toronto, Ontario).  The results also suggest that the rate of mitotically-derived 
CNVs is approximately three times higher than the rate of CNVs generated during 
parental meiosis. Some of this data is has been previously published in Maiti et 
al., 2011. 
2. This study observed an exceptional 13q deletion containing 38 CNVs at a single 
genomic location present in the father in family 2 (II-1-1). 
An exceptional and unexplained finding of this study was the CNV quantity and 
distribution found in the genome of the father in family 2 (II-1-1) who was found to 
harbour a rare chromosome 13q deletion. This deletion starts from cytoband position 
13q14.2 and ends at 13q21.32 and contains a loss of 38 CNVs. Although this finding is 
beyond the scope of this study, it is important to note that II-1-1 underwent chemotherapy 
treatment and that the samples utilized in this study were obtained towards the end of this 
treatment (Maiti et al., 2011). 
3. Different analytical tools on same data may result in similar but different results. 
The underlying statistical models for the several copy number variation calling methods 
evaluated in this study diverged by varying degrees. The primary raw data used for 
calling the CNVs from the Affymetrix
®
 Genome-Wide Human SNP Array 6.0 were the 
SNP intensity signals measured by logR ratios, however some of the methods also used B 
allele frequencies. Principally, all data analysis packages mainly used Hidden Markov 
Model (HMM) for calling copy number variation but how this model was used by each 
platform differed slightly. Affymetrix
®
 Genotyping Console
TM
  uses median log2 ratio 
values of all contiguous SNPs in the given HMM copy number state segment. Partek
®
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Genome Suite
TM
 also uses HMM algorithm but evaluates discrete changes of whole 
number copy number states. The PennCNV program uses the combined logR ratio and B 
allele frequency. GTC developed their algorithm for analyzing the Affymetrix
®
 SNP 
array data, whereas non-Affymetrix platforms such as the PGS and PennCNV have 
developed their algorithms for use with both Illumina and Affymetrix
®
 SNP arrays. This 
study observed significant of variability among the results obtained using Affymetrix, 
Partek and PennCNV algorithms. The observed CNV frequency distribution was found to 
be different in family members for both families, and highly dependent on platform. GTC 
identified more than 86 and 87 percent gains in the twins of family 1 whereas PGS and 
PennCNV identified only 40, 47 percent and 54, 40 percent respectively. Similarly, in 
family 2, GTC found 88 and 91 percent gains in twin pairs one and two, whereas PGS 
and PennCNV found 36 and 29 percent, and 29 and 26 percent, respectively. In the case 
of CNV size distribution (Dalila Pinto et. al., 2011), this study observed that GTC was 
able to identify relatively small CNVs, primarily 100 to 200 kb in size.  PGS and 
PennCNV identified only larger CNVs between 1 Mb to 20 Mb in size for both families. 
Surprisingly, among all copy number variation identified, there were only 6 CNVs 
commonly identified with all platforms and in both families.  
4.2 Caveats 
Microarrays are a hybridization method that currently needs further validation with 
resequencing.  At the very least, data should be regenerated using one more hybridization 
method. Other than whole genome sequencing, all kinds of array-based methods identify 
only known variants in the human genome. As far as data analysis of the raw array data 
files, each analytical tool has their own algorithm that is based on specific hypotheses. As 
a result, depending on what questions or null hypothesis is asked by a given investigator, 
the final outcome may be quite different. So, analysis of same microarray raw data using 
multiple packages does not nullify the necessity of a discovery algorithm that meets the 
criteria of a researcher’s specific interest. Lastly, in silico findings require confirmation 
by biological approaches and should be revalidated by methods such as quantitative PCR. 
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4.3 Future studies 
Follow-up studies can be planned using the same set of individual samples and data in 
multiple ways. First, the microarray data can be generated using another platform 
available from other array providers, such as Illumina Inc. (San Diego, CA, USA). Raw 
microarray data generated from these platforms can be analyzed using the same set of 
CNV-calling tools and the results can be compared for percent overlap of results. 
Secondly, using the same set of samples, we can generate data using whole genome 
sequencing. The outcome of these results can be used to detect and confirm copy number 
variation that had previously been determined using microarray data. Nevertheless, given 
the state of the current technology, it is prudent to utilize more than a single detection 
method and CNV-calling algorithm to test any result for consistency and reproducibility.  
4.4 Novelty of the study 
We (and others) have shown that monozygotic twins are not genetically identical (Maiti 
et al., 2011, Bruder et. al., 2008). Copy number variations may contribute the phenotypic 
discordance observed even in monozygotic twins. These structural variants are very fluid 
and thus may play a major role in evolution. In this study, we have also evaluated and 
revalidated findings obtained with Affymetrix technology to examin the reliability of the 
obtained results. Here, the result of an Affymetrix array and analysis platform has been 
re-tested with Partek and PennCNV, two alternative packages that utilize very different 
algorithms than Affymetrix and each other. To provide further validity to the detected 
CNVs, the same raw data analyzed with different packages and algorithms, which 
resulted in six CNVs confirmed by all three. These results highlight these CNVs for 
future study, suggesting that they may be good candidates for further research towards the 
identification of a genetic basis of the twins’ discordance for schizophrenia.  
Every microarray data analysis platform possesses its own algorithm that is limited by 
how it evaluates a specific null hypothesis, thus making one package restricted in its 
ability to identify losses or gains of CNVs of a specific size or other criteria. This study 
demonstrates the scientific hazards of interpreting results scored with single package. The 
familial inheritance of CNVs varies from one family to another. Further, although all 
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three algorithms have demonstrated that monozygotic twins do not share genetic 
homogeneity, exactly how they may differ requires careful and precise identification, 
particularly in the case of examining the causes of discordance for genetic diseases.  
4.5 Original contribution  
This study identified several de novo CNVs that differ between co-twins. This study also 
identified three novel CNVs which were not previously listed in the Database of Genomic 
Variants (Toronto, Ontario) (now submitted). Of these three CNVs, two were gains and 
one was a loss of a CNV in chromosomal locations 8q11.21, 19q13.41 and 14q32.11 
respectively. 
4.6 Conclusions 
In this study, the genomic DNA of discordant monozygotic twins and their families were 
analyzed to identify and characterize the genomic structural variation (copy number 
variation) that existed between monozygotic twins and their parents. The study of copy 
number variation in families containing monozygotic twin pairs is a new and rapidly-
evolving field. Microarray data are becoming a very powerful source to indentify copy 
number variation. Different algorithms use different statistical methods to identify and 
classify copy number variations. The goal of this study was to evaluate the existence and 
potential role of genetic variants in the monozygotic twins, and stress the importance of 
statistical methods or algorithms to identify these genetic variants. 
The central outcomes from this research are listed below: 
1. Monozygotic twins differ in copy number variation (CNV) and are not 100% 
genetically identical, as expected. CNVs may be either inherited from their 
parents or acquired during their development. It is the de novo differences, 
however, that may cause genetic differences between monozygotic twins and may 
be responsible for phenotypic differences.  
2. Different analytical algorithms for calling CNVs may yield variable results from 
the same microarray data.  
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3. This study observed an exceptional 13q deletion containing 38 CNVs at a single 
genomic location, present in the father in family 2 (II-1-1). 
4. There is yet a need to develop reliable analytical methods to identify genetic 
variations from microarray results.  
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Appendix Table 1: de novo CNVs in Family 1 identified by GTC. 
 
Identity of de novo CNVs found in Family 1 ( Table 5) and the gene regions (overlapping or nearby). De novo CNVs are defined as those 
that are present in either or both twins but not found in parents. SD displays the percentage of overlap with segmental duplications, ‘0’ 
indicates no overlap between the CNV and segmental duplication and ‘1’ indicates 90-100% overlap. The table includes genomic locations 
as well as twin specific breakpoints which allow for the assessment of regions of overlap with the Database of Genomic Variants (Toronto, 
ntario). SI No. = Serial number. Novel indicates a CNV which is not present in The Database of Genomic Variants (DGV).   
Sl. No Location 
Family 1 
Status Meiosis Mitosis Novel 
Genes  
(Overlapping or 
Nearby) 
SD 
I-2-1 Size (kb) Breakpoints I-2-2 Size (kb) Breakpoints 
1 1p36.13 Yes 112 16724089...16835888 
   
Gain 
 
Yes 
 
NBPF1, NBPF10 1 
2 2p25.3 Yes 152 1407209...1559511 Yes 152 1407209...1559511 Gain Yes 
  
TPO 0 
3 2p11.2 Yes 1147 89862331...91008912 Yes 1159 89850279...91008912 Loss Yes 
   
0 
4 4q28.3 
   
Yes 191 132801221...132992517 Gain 
 
Yes 
  
1 
5 7q11.21 Yes 118 64706066...64823721 Yes 118 64704377...64822216 Loss Yes 
   
1 
6 8p23.1 Yes 126 7847289...7973253 
   
Loss 
 
Yes 
  
1 
7 8q11.1 Yes 336 47045602...47381308 Yes 250 47131383...47381308 Gain Yes 
   
0 
8 8q11.21 
   
Yes 154 48178242...48332398 Loss 
 
Yes Yes KIAA0146 0 
9 9p11.2 Yes 569 45361389...45929992 
   
Gain 
 
Yes 
 
FAM27A 1 
10 9p13.1 
   
Yes 141 38777481...38918566 Gain 
 
Yes 
  
1 
11 9q12 
   
Yes 861 65412415...66273526 Gain 
 
Yes 
  
1 
12 12p13.31 
   
Yes 196 8303317...8499801 Gain 
 
Yes 
 
CLEC6A 1 
13 14q32.11 
   
Yes 103 89780137...89883415 Loss 
 
Yes Yes PSMC1, C14orf102 0 
14 21q11.2 
   
Yes 119 13891136...14009908 Gain 
 
Yes 
 
ANKRD21, LOC441956 1 
15 Xp11.23 Yes 149 47917899...48066856 Yes 149 47917899...48066856 Gain Yes 
  
SSX5, SSX1, SSX9 0 
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Appendix Table 2: de novo CNVs in Family 2 by GTC. 
 
Sl. No Location 
Family 2 
Status Meiosis Mitosis Novel 
Genes  
(Overlapping or Nearby) 
S
D II-2-1 Size (kb) Breakpoints II-2-2 Size (kb) Breakpoints 
1 1q21.1 
   
Yes 120 143867807...143987616 Gain 
 
Yes 
 
NOTCH2NL 0 
2 1q21.1 Yes 104 147353175...147456930 Yes 104 147353175...147456930 Loss Yes 
   
0 
3 1q43 
   
Yes 119 241230453...241349107 Gain 
 
Yes 
  
0 
4 3q21.2 Yes 155 126958012...127112518 
   
Gain 
 
Yes 
  
1 
5 4p11 Yes 299 48986100...49285347 
   
Gain 
 
Yes 
  
0 
6 5p15.33 Yes 101 770367...871743 Yes 107 770367...877436 Gain Yes 
  
ZDHHC11 1 
7 5p13.3 Yes 151 34119387...34269887 
   
Gain 
 
Yes 
  
1 
8 7q11.21 Yes 202 61761008...61962936 
   
Gain 
 
Yes 
  
0 
9 7q11.21 Yes 116 64588316...64704125 Yes 125 64579322...64704125 Gain Yes 
   
1 
10 7q35 
   
Yes 100 142956516...143056637 Gain 
 
Yes 
 
LOC441294, FAM139A 1 
11 8p23.1 Yes 220 12071704...12291845 Yes 220 12071704...12291845 Gain Yes 
  
FAM86B1, DEFB130 0 
12 9p12 Yes 2720 41465094...44184864 Yes 1901 42249132...44149779 Gain Yes 
  
ANKRD20A2, ANKRD20A3, 
FOXD4L4, FOXD4L2 
1 
13 9q12 
   
Yes 250 67416254...67665974 Gain 
 
Yes 
 
ANKRD20A1,  ANKRD20A3 1 
14 11q13.2 Yes 267 67239223...67505822 Yes 139 67239223...67378031 Gain Yes 
   
1 
15 12p13.31 
   
Yes 189 8310909...8499801 Gain 
 
Yes 
  
1 
16 13q11 Yes 208 18138676...18346383 
   
Gain 
 
Yes 
  
1 
17 14q11.1 Yes 601 18072112...18672662 Yes 601 18072112...18672662 Gain Yes 
  
OR11H12, ACTBL1 1 
18 15q11.1 
   
Yes 106 18276329...18382609 Gain 
 
Yes 
  
1 
19 15q11.2 Yes 203 19882763...20085783 Yes 221 19864583...20085783 Gain Yes 
  
OR4M2, OR4N4, LOC650137 1 
20 15q13.1 
   
Yes 227 26808083...27035216 Gain 
 
Yes 
 
APBA2 0 
21 15q13.2 Yes 110 28452853...28563274 
   
Gain 
 
Yes 
 
CHRFAM7A 1 
22 17p11.1 Yes 199 22127012...22326425 
   
Gain 
 
Yes 
  
0 
23 19q13.41 Yes 109 58847652...58957090 
   
Gain 
 
Yes Yes ZNF331, DPRX 0 
24 20q11.1 
   
Yes 118 28147331...28264860 Gain 
 
Yes 
  
1 
25 21p11.2 Yes 3480 10106540...13586186 Yes 3814 9758730...13572586 Gain Yes 
  
BAGE2, BAGE4, BAGE 0 
 
Identity of de novo CNVs found in Family 2 (Table 7) and the gene regions (overlapping or nearby). De novo CNVs are defined as those 
that are present in either or both twins but not found in parents. SD displays the percentage of overlap with segmental duplications, ‘0’ 
indicates no overlap between the CNV and segmental duplication and ‘1’ indicates 90-100% overlap. The table includes genomic locations 
as well as twin specific breakpoints which allow for the assessment of regions of overlap with the Database of Genomic Variants (Toronto, 
Ontario). SI No. = Serial number. Novel indicates a CNV which is not present in The Database of Genomic Variants (DGV).
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Appendix Table 3: Inherited CNVs in Family 1 by GTC. 
 
 
 
 
 
 
 
 
 
 
Sl. 
No 
Location 
Family 1 
Status Novel 
Genes  
(Overlapping or Nearby) 
SD I-1-
1 
Size(kb) Breakpoints 
I-1-
2 
Size(kb) Breakpoints 
I-2-
1 
Size(kb) Breakpoints 
I-2-
2 
Size(kb) Breakpoints 
1 1p36.33 Yes 167 51586...218557 
   
Yes 707 51586...758644 Yes 707 51586...758644 Gain 
 
OR4F5, OR4F3, OR4F16, OR4F29 1 
2 1q21.1 Yes 765 147303136...148068045 Yes 734 147311699...148045353 
   
Yes 577 147381253...147958358 Gain 
 
PPIAL4, FCGR1A, HIST2H2BF 1 
3 2p11.2 Yes 338 88917155...89254935 Yes 322 88914734...89236978 Yes 325 88917155...89242149 Yes 327 88914734...89242149 Gain 
  
1 
4 2p11.1 
   
Yes 138 91017077...91154841 Yes 143 91017077...91160399 Yes 137 91017077...91154463 Gain 
  
1 
5 2q21.2 Yes 236 132597824...132833718 
   
Yes 222 132597824...132819911 Yes 222 132597824...132819911 Gain 
  
1 
6 3p12.3 Yes 306 75677859...75984129 Yes 380 75597086...75977210 Yes 182 75583442...75764996 Yes 402 75582277...75984129 Gain 
  
1 
7 3q21.2 
   
Yes 132 126907150...127039328 
   
Yes 185 126907150...127091652 Gain 
  
1 
8 3q21.3 
   
Yes 170 131198515...131368353 Yes 166 131213377...131379054 Yes 176 131214431...131389948 Gain 
  
1 
9 4p16.2 
   
Yes 196 4040542...4236511 Yes 363 3873500...4236511 Yes 366 3870638...4236511 Gain 
  
0 
10 4p11 Yes 436 48849363...49285347 
   
Yes 497 48788531...49285347 Yes 497 48788531...49285347 Gain 
  
1 
11 4q35.2 Yes 232 191021837...191254119 Yes 195 191059369...191254119 
   
Yes 223 191031042...191254119 Gain 
 
FRG1, TUBB4Q, FRG2, DUX4 0 
12 7p11.1 Yes 231 57523223...57753919 Yes 101 57640100...57741512 Yes 315 57640100...57954861 Yes 117 57640100...57757406 Gain 
  
1 
13 7q11.21 
   
Yes 112 61365830...61477958 
   
Yes 111 61365830...61476918 Gain 
  
0 
14 7q11.21 
   
Yes 253 64320173...64573380 Yes 415 64204380...64619667 Yes 385 64204380...64589253 Loss 
 
ZNF92 0 
15 8p23.1 Yes 694 7209579...7903560 
   
Yes 215 7027251...7242508 Yes 270 7021193...7291135 Loss 
 
DEFB103A, DEFB103B, SPAG11B, 
DEFB104B, DEFB104A, DEFB106B, 
DEFB106A, DEFB105B, DEFB105A, 
DEFB107B, DEFB107A, SPAG11A, 
DEFB4 
2 
16 9q12 
   
Yes 690 68115006...68805366 Yes 1141 68115006...69256300 Yes 694 68115006...68809437 Gain 
 
FOXD4L6, CBWD6,  
ANKRD20A4, CCDC29 
1 
17 10q11.1 Yes 183 41972779...42155347 Yes 105 41934430...42039743 Yes 183 41972779...42155347 Yes 239 41934430...42173117 Gain 
  
1 
18 11p15.4 Yes 175 3405799...3580813 Yes 131 3430789...3561991 Yes 139 3430789...3569305 Yes 156 3406002...3561991 Gain 
  
1 
19 11q13.2 Yes 227 67239223...67466368 
   
Yes 193 67273413...67466368 
   
Gain 
  
1 
20 14q11.1 Yes 1322 18138794...19460382 Yes 1103 18072112...19175240 Yes 705 18072112...18776746 Yes 705 18072112...18776746 Gain 
 
OR11H12, ACTBL1, OR4Q3, 
 OR4M1, OR4N2, OR4K5 
0 
21 14q32.33 Yes 126 105265510...105391419 Yes 167 105100670...105268160 Yes 632 105190672...105822317 Yes 181 105149735...105331052 Gain 
  
0 
  
Yes 156 105413825...105569826 Yes 213 105289618...105502685 Yes 178 105827891...106005581 Yes 261 105341035...105601720 Gain 
  
0 
  
Yes 205 105612786...105818132 Yes 279 105508896...105788389 
   
Yes 280 105612786...105892769 Gain 
  
0 
22 15q11.1 Yes 471 18370252...18841457 Yes 178 18522238...18700540 Yes 1223 18845990...20068512 Yes 562 18276329...18838423 Gain 
 
LOC283755, POTE15, OR4M2 1 
  
Yes 1177 18845990...20022565 Yes 344 18845990...19189673 
   
Yes 1078 18845990...19923712 Gain 
 
OR4N4, LOC650137 1 
     
Yes 264 19303160...19566863 
      
Gain 
  
1 
23 15q11.2 Yes 189 22026287...22214843 
      
Yes 174 22026287...22200408 Gain 
  
1 
24 16p11.2 Yes 1217 32303108...33520394 Yes 1297 32538757...33836128 Yes 1142 32538757...33680554 Yes 249 32538757...32787273 Gain 
 
LOC729355, TP53TG3 1 
           
Yes 752 32910319...33662480 Gain 
  
1 
25 16p11.2 Yes 250 34374795...34624994 
   
Yes 249 34375533...34624994 Yes 249 34375533...34624994 Gain 
  
1 
26 17p11.2 Yes 140 20559979...20700133 
      
Yes 164 20538867...20703365 Gain 
  
1 
27 17q21.31 Yes 229 41521621...41750183 
   
Yes 123 41521621...41644356 Yes 123 41521621...41644356 Gain 
 
KIAA1267, LRRC37A 0 
28 17q21.31 Yes 351 41756820...42107467 Yes 296 41811739...42107467 Yes 392 41700624...42092926 Yes 302 41700624...42002447 Gain/Loss 
 
ARL17, LRRC37A2, NSF 1 
29 21p11.2 
   
Yes 204 9758730...9962501 Yes 204 9758730...9962501 Yes 204 9758730...9962501 Gain 
 
TPTE 0 
30 21p11.1 Yes 3411 10106540...13517603 Yes 3419 10106540...13525448 Yes 3419 10106540...13525448 Yes 3477 10106540...13583117 Gain 
 
BAGE2, BAGE4, BAGE 2 
31 22q11.1 Yes 339 14435171...14774593 
   
Yes 320 14435207...14754960 Yes 320 14435207...14754960 Gain 
 
ACTBL1 1 
32 22q11.21 Yes 124 20051708...20175282 
   
Yes 136 20145854...20281562 Yes 136 20145854...20281562 Gain 
 
HIC2, UBE2L3 1 
33 22q11.22 Yes 240 21292462...21532509 
   
Yes 127 21327799...21454509 
   
Gain 
 
GGTL4 0 
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Appendix Table 4: Inherited CNVs in Family 2 by GTC. 
 
Sl. 
No 
Location 
Family 2 
Status Novel 
Genes  
(Overlapping or Nearby) 
SD II-1-
1 
Size(kb) Breakpoints 
II-1-
2 
Size(kb) Breakpoints 
II-2-
1 
Size(kb) Breakpoints 
II-2-
2 
Size(kb) Breakpoints 
1 1p36.33 Yes 707 51586...758644 
   
Yes 537 218557...755132 
   
Gain 
 
OR4F5, OR4F3, OR4F16, 
OR4F29 
1 
2 1p36.13 Yes 117 16718622...16835888 
   
Yes 167 16718622...16885360 Yes 345 16718622...17063437 Gain 
 
NBPF1, NBPF10 1 
3 1p21.1 
   
Yes 130 103910749...104041200 Yes 127 103931691...104058426 
   
Gain 
 
AMY2B, AMY2A, AMY1A,  
AMY1C, AMY1B 
1 
4 1p11.2 Yes 21680 121045307...142725034 
   
Yes 21725 121045307...142770353 Yes 21725 121045307...142770353 Gain 
  
0 
5 1q23.3 Yes 121 159775403...159896554 
   
Yes 116 159780383...159896554 Yes 121 159775403...159896554 Loss 
 
FCGR3A, FCGR2C, 
FCGR3B 
1 
6 2p11.2 Yes 401 88925215...89326446 Yes 759 88914227...89673147 Yes 935 88926972...89861763 Yes 450 88914734...89365010 Gain 
  
1 
7 2p11.1 Yes 160 91017077...91176948 
   
Yes 268 91017077...91285520 Yes 1275 89879561...91154463 Gain 
  
1 
8 2q21.2 Yes 260 132593436...132853218 Yes 183 132597824...132780848 
   
Yes 222 132597824...132819911 Gain 
  
1 
9 3p12.3 Yes 260 75583442...75843060 Yes 226 75538978...75764996 Yes 260 75583442...75843060 Yes 182 75583442...75764996 Gain 
  
1 
10 3q12.2 Yes 108 101822746...101930873 
   
Yes 102 101822746...101925168 
   
Gain 
 
GPR128, TFG 0 
11 3q21.3 
   
Yes 141 131198817...131339424 Yes 195 131194669...131389948 Yes 199 131198515...131397648 Gain 
  
1 
12 4p16.2 Yes 407 3870638...4278016 Yes 180 3964803...4144453 Yes 366 3870638...4236511 Yes 357 3870638...4227503 Gain 
 
OTOP1 0 
13 4q35.2 Yes 200 191053845...191254119 
   
Yes 226 191028537...191254119 Yes 158 191052245...191210542 Gain 
 
FRG1, TUBB4Q, FRG2, 
DUX4 
0 
14 7p22.1 Yes 157 6838697...6995298 
      
Yes 155 6840798...6995298 Gain 
  
1 
15 7p11.1 Yes 117 57640100...57757406 Yes 114 57640100...57753919 Yes 149 57604989...57753919 Yes 123 57597399...57720623 Gain 
  
1 
16 8p23.1 Yes 203 12415742...12618442 
   
Yes 199 12415742...12614748 Yes 136 12415742...12551430 Gain 
  
1 
17 8p11.23 Yes 139 39349470...39488053 Yes 151 39354748...39506110 Yes 133 39354748...39488053 Yes 151 39354748...39506110 Loss 
  
0 
18 9p11.2 Yes 21937 44336683...66273526 
   
Yes 21015 45258754...66273526 Yes 21015 45258754...66273526 Gain 
 
FAM27A, FAM75A7 0 
 
9q12 Yes 861 68352238...69213455 Yes 103 68115006...68218485 Yes 1180 68076544...69256300 Yes 1099 68115006...69213671 Gain 
 
FOXD4L6, CBWD6, 
ANKRD20A4,  
CCDC29 
1 
     
Yes 457 68352238...68809437 
      
Gain 
 
19 10q11.1 Yes 129 41974796...42103488 Yes 236 41934430...42170853 Yes 105 41934430...42039743 Yes 239 41934430...42173117 Gain 
  
1 
20 11p15.4 Yes 206 3383178...3588946 
   
Yes 205 3376078...3580813 Yes 131 3430789...3561991 Gain 
  
1 
21 14q11.2 
   
Yes 186 21602854...21788783 Yes 172 21625813...21787161 
   
Loss 
  
0 
22 14q11.2 
   
Yes 226 21804698...22030660 Yes 226 21804698...22030660 
   
Loss 
  
0 
23 14q32.33 Yes 386 105190672...105576359 Yes 253 105345270...105597999 Yes 411 105190672...105601397 Yes 336 105265510...105601397 Gain 
  
0 
24 14q32.33 Yes 137 105760582...105897672 Yes 173 105645593...105818132 Yes 150 105638133...105788389 Yes 182 105640496...105822317 Gain 
  
0 
25 15q11.2 
   
Yes 156 18682380...18838423 Yes 183 18655531...18838423 Yes 156 18682380...18838423 Gain 
 
LOC283755, POTE15 1 
     
Yes 1067 18861808...19928521 Yes 572 18850029...19422452 Yes 344 18845990...19189673 Gain 
 
OR4M2, OR4N4, 
LOC650137 
1 
           
Yes 624 19207088...19835514 Gain 
  
1 
26 15q25.3 
   
Yes 161 83524791...83685356 Yes 228 83524791...83752853 Yes 228 83524791...83752450 Gain 
 
AKAP12 0 
27 15q25.3 
   
Yes 123 83784507...83907801 Yes 157 83784507...83941483 Yes 159 83790259...83949305 Gain 
 
AKAP13 0 
28 16p11.2 Yes 118 31882658...32000323 
   
Yes 1131 32531735...33662480 Yes 1377 32303108...33680554 Gain 
 
LOC729355, TP53TG3 1 
  
Yes 294 32088275...32382422 
         
Gain 
  
1 
  
Yes 185 32538757...32723310 
         
Gain 
  
1 
  
Yes 474 32962147...33436245 
         
Gain 
  
1 
  
Yes 211 33451476...33662480 
         
Gain 
  
1 
29 17q21.31 Yes 586 41521621...42107467 Yes 198 41521621...41719935 Yes 586 41521621...42107467 Yes 407 41700624...42107467 Gain 
 
KIAA1267, LRRC37A, 
ARL17, 
 LRRC37A2, NSF 
1 
30 18p11.21 Yes 1545 15262486...16807594 
      
Yes 130 15218647...15348836 Gain 
 
ROCK1 1 
31 19q13.31 Yes 116 47991257...48107552 
   
Yes 133 47991257...48123857 Yes 235 47986218...48221228 Loss 
 
PSG1, PSG6, PSG7, PSG11 1 
32 21p11.2 Yes 204 9758730...9962501 Yes 204 9758730...9962501 Yes 204 9758730...9962501 
   
Gain 
 
TPTE 0 
33 22q11.22 Yes 148 21300127...21448190 
   
Yes 200 21298324...21498767 Yes 178 21298324...21476564 Gain 
 
GGTL4 0 
34 Xp11.23 Yes 112 47917899...48029446 Yes 269 47917899...48186708 Yes 184 47917899...48102337 Yes 257 47935225...48192383 Gain 
 
SSX5, SSX1, SSX9, SSX3 1 
35 Xq13.1 Yes 185 71869375...72054837 
      
Yes 185 71869375...72054837 Gain Yes DMRTC1 1 
101 
 
Identity of inherited CNVs found in Family 1, Family 2 and the gene regions which they 
overlap. Inherited CNVs are those which are present in either or both parents and 
transmitted to either or both twins. All size is in kb. SD indicates the percentage of 
overlap between segmental duplications and CNVs. ‘0’ means there is no overlap 
between CNV and segmental duplication, ‘1’ means 90-100% and ‘2’ means 50-90% 
overlap.  Parental CNVs not transmitted to offspring were not included in inherited and 
de novo Table so the total number of CNVs present in Table 2-4 was not same as 
inherited and do novo Table. The table includes genomic locations as well as individual 
specific break points which allow for the assessment of regions of overlap with the 
Database of Genomic Variants (Toronto, Ontario). SI No. = Serial number. Novel 
indicates a CNV which is not present in The Database of Genomic Variants (DGV).  
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Appendix Table 5: de novo CNVs in Family 1 identified by PGS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl. No. Location I-2-1 I-2-2 Gene 
1 1p36.11 Gain Gain RHD 
2 1p21.1 Loss     
3 2p25.3 Gain Gain TPO 
4 2q22.3 Loss     
5 3p24.1 Loss Loss   
6 3p Loss Loss EPHA3 
7 4q13.2 Gain Gain   
8 4q28.3   Loss   
9 4q34.1 Gain Gain GALNTL6 
10 4q34.1   Gain GALNTL6 
11 4q34.3 Loss   LOC285501 
12 5p Gain Gain   
13 6p21.33 Gain Gain   
14 7q34 Gain Gain   
15 8p23.3 Loss Loss   
16 9q21.13   Gain   
17 10p12.1 Loss     
18 10q26.12 Loss Loss   
19 12q12 Loss Loss   
20 13q21.31   Loss OR7E156P 
21 15q11.2 Loss Loss   
22 16q22.1 Loss Loss PDPR, CLEC18C 
23 18q22.1 Loss     
24 19q13.2 Gain     
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Appendix Table 6: de novo CNVs in Family 2 identified by PGS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl. No. Location II-2-1 II-2-2 Gene 
1 1p31.1   Loss   
2 1p13.3   Loss GSTM1 
3 1q31.1 Loss     
4 2p23.3 Loss Loss   
5 2q33.3 Loss Loss   
6 3q21.2 Loss Loss   
7 4q12   Gain   
8 5p15.2 Gain     
9 5p13.3 Gain Gain   
10 5q14.2 Loss   ATG10 
11 6p21.33 Loss Loss   
12 6q14.1   Loss   
13 7q33 Loss Loss   
14 7q33   Loss   
15 8p11.23 Loss Loss ADAM5P, ADAM3A 
16 8p11.23 Loss   ADAM3A 
17 8q23.3   Loss   
18 8q23.3   Loss   
19 9p21.3 Gain     
20 10q11.22   Loss   
21 10q21.3 Gain Gain   
22 10q26.13   Loss DMBT1 
23 11p15.1   Gain MRGPRX1 
24 11p11.12 Loss Loss LOC440040 
25 12p Loss Loss   
26 16q12.2 Gain   CES4 
27 18q12.3 Loss Loss   
28 19q13.12   Loss   
29 22q11.23   Gain 
GSTT2B, GSTT2, DDTL, 
DDT, GSTTP1 
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Appendix Table 7: Inherited CNVs in Family 1 by PGS. 
 
Sl. No. Location I-1-1 I-1-2 I-2-1 I-2-2 Gene 
1 1p34.3   Loss Loss Loss   
2 1p21.1   Loss Loss Loss   
3 1q21.3 Loss   Loss Loss LCE1E, LCE1D 
4 1q31.3 Loss     Loss   
5 2p11.2 Loss   Loss Loss   
6 2q11.2 Gain     Gain ANKRD36B 
7 3q21.2 Loss   Loss Loss   
8 3q26.1   Loss Loss Loss   
9 4q12 Loss   Loss   HOPX 
10 4q13.2 Gain   Gain Gain UGT2B17 
11 4q34.1 Gain   Gain Gain   
12 5p15.2   Gain Gain Gain   
13 5q11.2 Loss   Loss Loss RAB3C 
14 5q23.1   Loss Loss Loss COMMD10 
15 6q14.1 Gain   Gain     
16 7q11.21   Loss Loss Loss INTS4L1, ZNF92 
17 7q34 Gain   Gain Gain TRY6 
18 8p23.1 Loss   Loss Loss 
DEFB103A, DEFB103B, 
SPAG11B, DEFB104B, 
DEFB104A, DEFB106B, 
DEFB106A, DEFB105B, 
DEFB105A, DEFB107A, 
DEFB107B, FAM90A7, 
SPAG11A, DEFB4, 
FAM66E, DEF109P1B 
19 8p21.2 Gain   Gain Gain   
20 8p11.23 Gain Gain Gain Gain ADAM5P ADAM3A 
21 9p21.3   Loss Loss Loss   
22 10q21.3 Gain   Gain Gain   
23 11p15.4 Gain Gain Gain Gain OR51A2 
24 11p15.4   Loss Loss Loss OR52N5, OR52N1 
25 13q21.33 Loss   Loss Loss   
26 14q32.33   Gain Gain Gain   
27 18q22.1   Loss Loss     
28 22q11.21 Gain   Gain Gain PI4KAP2 
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Appendix Table 8: Inherited CNVs in Family 2 by PGS. 
 
Sl. No. Location II-1-1 II-1-2 II-2-1 II-2-2 Gene 
1 1p31.1   Gain Gain Gain   
2 1p21.1   Gain Gain Gain 
AMY2A, AMY1A, 
AMY1C, AMY1B 
3 1q21.1   Loss Loss Loss   
4 1q21.3   Loss Loss Loss LCE3C 
5 2p22.3   Gain Gain Gain   
6 2p16.3   Loss Loss Loss   
7 2q33.1   Loss Loss Loss   
8 2q37.1 Loss     Loss   
9 3p26.1 Gain   Gain Gain   
10 3q12.2 Gain   Gain Gain GPR128, TFG 
11 4q13.2 Loss   Loss Loss UGT2B28 
12 4q32.2 Loss Loss Loss Loss   
13 4q34.1 Loss Loss Loss Loss   
14 4q34.1 Loss   Loss Loss GALNTL6 
15 5p15.1 Loss Loss Loss Loss   
16 5q11.2 Gain Gain   Loss   
17 6q13 Loss   Loss Loss   
18 6q14.1   Loss Loss Loss   
19 6q16.3 Gain   Gain Gain   
20 6q21   Loss Loss Loss   
21 6q27   Gain Gain Gain RPS6KA2 
22 7q21.13 Loss   Loss Loss   
23 8p21.2   Loss Loss Loss   
24 10p12.1 Loss Loss Loss Loss KIAA1217 
25 11p15.4   Loss Loss Loss OR51A4 
26 11q22.3 Loss   Loss Loss CASP12 
27 12p13.31 Gain Gain Gain Gain   
28 12p11.22   Loss Loss     
29 13q13.3 Gain   Gain Gain   
30 14q   Loss Loss   
POTEG, P704P, OR4Q3, 
OR4M1, OR4N2, OR4K5, 
OR4K1 
31 14q32.33 Loss   Loss Loss   
32 15q25.3   Gain Gain Gain AKAP13 
33 16q23.1   Gain Gain Gain CHST5, FLJ22167 
34 16q23.1   Loss Loss Loss WWOX 
35 17q21.31 Gain   Gain Gain ARL17, LRRC37A2, 
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ARL17P1, NSF 
36 19q13.31 Loss   Loss Loss 
PSG10, PSG1, PSG6, 
PSG7, PSG11 
37 20p13   Loss Loss Loss SIRPB1 
38 20q12   Loss Loss Loss PTPRT 
39 22q11.23   Loss   Loss GSTTP1 
40 22q11.23   Loss Loss Loss GSTT1, GSTTP2 
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Appendix Table 9: de novo CNVs in Family 1 identified by PennCNV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl. 
No. 
Location I-2-1 I-2-2 Gene 
1 1p31.1 Gain Gain   
2 2q22.3 Loss Loss   
3 5p Gain     
4 5q11.2   Loss RAB3C 
5 7q33 Gain Gain   
6 7q34 Gain Gain   
7 8p23.1 Loss Loss FAM66E, DEF109P1B 
8 10p12.1 Gain   KIAA1217 
9 11q22.3   Loss CWF19L2 
10 15q11.2 Loss Loss   
11 15q26.3   Loss OR4F4 
12 16q23.1 Gain   WWOX 
13 22q11.23   Gain 
LOC391322, GSTT1, 
GSTTP2 
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Appendix Table 10: de novo CNVs in Family 2 identified by PennCNV. 
 
 
 
Sl. No. Location II-2-1 II-2-2 Gene 
1 2p23.3   Loss   
2 2q33.3 Loss Loss   
3 4q34.1   Loss   
4 5p13.3   Gain PDZD2, GOLPH3 
5 6p21.33 Loss     
6 6p21.32   Loss   
7 6q16.3 Gain Gain   
8 6q21   Loss   
9 7q33 Loss Loss   
10 8p23.1   Gain 
DEFB103A, DEFB103B, 
SPAG11B, DEFB104B, 
DEFB104A, DEFB106B, 
DEFB106A, DEFB105B, 
DEFB105A, DEFB107A, 
DEFB107B, FAM90A7 
11 11p15.1 Gain Gain MRGPRX1 
12 12p11.22 Loss     
13 13q12.12 Loss Loss   
14 14q11.2   Loss OR4K2 
15 18q12.3 Loss Loss   
16 19q13.31 Loss Loss PSG10, PSG1, PSG6, PSG7 
17 
22q11.23   Loss 
GSTTP1, LOC391322, 
GSTTP2 
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Appendix Table 11: Inherited CNVs in Family 1 by PennCNV. 
 
 
Sl. No. Location I-1-1 I-1-2 I-2-1 I-2-2 Gene 
1 1p34.3   Loss Loss Loss   
2 1p21.1 Gain Loss Loss Loss   
3 1q21.3 Loss   Loss Loss   
4 2p16.3   Gain Gain Gain   
5 2p11.2 Loss   Loss Loss   
6 3p   Loss Loss Loss EPHA3 
7 3q26.1   Loss Loss Loss   
8 4q13.2 Gain   Gain Gain 
TMPRSS11E, 
TMPRSS11E2, UGT2B17 
9 4q32.2 Gain   Gain     
10 4q34.1 Gain   Gain Gain   
11 4q34.1 Gain     Gain GALNTL6 
12 5q23.1   Loss Loss Loss COMMD10 
13 7q11.21 Gain Loss Loss Loss INTS4L1, ZNF92 
14 7q34 Gain   Gain   TRY6 
15 8p23.1 Loss     Loss 
DEF109P1B, DEFB103A, 
DEFB103B, SPAG11B, 
DEFB104B, DEFB104A, 
DEFB106B, DEFB106A, 
DEFB105B, DEFB105A, 
DEFB107A, DEFB107B, 
FAM90A7, SPAG11A, 
DEFB4 
16 8p11.23 Gain Gain Gain Gain ADAM5P ADAM3A 
17 9p21.3   Loss Loss     
18 11p15.4 Gain Gain Gain Gain OR51A4, OR51A2 
19 11p15.4   Loss Loss Loss OR52N5, OR52N1 
20 14q Gain   Gain   
POTEG, P704P, OR4Q3, 
OR4M1, OR4N2, OR4K2, 
OR4K5, OR4K1 
21 14q32.33   Gain Gain Gain   
22 16p11.2 Gain   Gain Gain 
LOC283914, LOC283914, 
LOC146481 
23 22q11.21 Gain   Gain   
POM121L8P, RIMBP3C, 
RIMBP3B, HIC2, PI4KAP2 
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Appendix Table 12: Inherited CNVs in Family 2 by PennCNV. 
 
 
 
 
 
 
 
 
 
 
 
 
Sl. No. Location II-1-1 II-1-2 II-2-1 II-2-2 Gene 
1 1p31.1   Gain Gain Gain   
2 1p21.1   Gain Gain Gain   
3 1q21.1   Loss Loss Loss   
4 2p22.3 Loss   Gain     
5 3q12.2 Gain   Gain Gain GPR128, TFG 
6 4q13.2 Loss   Loss Loss UGT2B28 
7 4q32.2   Loss Loss Loss   
8 4q34.1 Loss     Loss GALNTL6 
9 6q14.1   Loss Loss Loss   
10 6q27   Gain Gain Gain RPS6KA2 
11 7q21.13 Loss   Loss Loss   
12 7q34 Loss   Loss Loss   
13 8p21.2   Loss Loss Loss   
14 8p11.23 Loss   Loss Loss 
ADAM5P, 
ADAM3A 
15 8q23.3 Loss     Loss   
16 10p12.1 Loss   Loss Loss KIAA1217 
17 11p15.4   Loss Loss Loss OR51A2 
18 14q32.33 Loss   Loss Loss   
19 15q25.3   Gain Gain Gain AKAP13 
20 16q23.1   Gain Gain Gain 
CHST5, 
FLJ22167 
21 16q23.1   Loss Loss Loss WWOX 
22 19q13.12 Loss   Loss Loss   
23 20p13   Loss Loss Loss SIRPB1 
24 20q12   Loss   Loss PTPRT 
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